,category,over_represented_pvalue,under_represented_pvalue,numDEInCat,numInCat,adjP,Pathway,DEgenesInCat
1,R-HSA-1474244,0,1,120,297,0,Extracellular matrix organization,LAMC3::P3H3::CAPN9::MMP24::ADAMTS8::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL13A1::COL15A1::COL16A1::COL17A1::COL19A1::COL26A1::ADAMTS14::VCAN::CTSV::DCN::ADAMTS16::ADAMTS18::FBN1::FBN2::EFEMP1::FGF2::FGG::COLGALT2::FN1::PCOLCE2::BMP10::LAMA1::EFEMP2::HSPG2::ICAM1::ICAM2::COL28A1::ITGA6::ITGA1::ITGA3::ITGA4::ITGA5::ITGB1::ITGB2::ITGB3::ITGB4::ITGB8::KLKB1::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::LOX::LOXL1::LOXL2::LRP4::LTBP2::LTBP3::MATN3::MFAP2::MMP2::MMP9::MMP14::MUSK::CEACAM6::NID1::SERPINE1::SPOCK3::P3H2::PRKCA::KLK7::ADAMTS9::NTN4::BGN::SDC4::P3H1::BMP2::BMP4::SPARC::SPP1::TGFB1::TGFB2::TGFB3::THBS1::TIMP1::TIMP2::ICAM5::TLL1::TNR::COL14A1::VTN::ADAM12::MFAP5::COL18A1::COL21A1::EMILIN2::LOXL4::FBN3::COL27A1::ADAM19::CAPN13::ADAMTS3::CD44::SH3PXD2A
2,R-HSA-1474290,0,1,48,90,0,Collagen formation,P3H3::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL13A1::COL15A1::COL16A1::COL17A1::COL19A1::COL26A1::ADAMTS14::CTSV::COLGALT2::PCOLCE2::COL28A1::ITGA6::ITGB4::LAMA3::LAMB3::LAMC2::LOX::LOXL1::LOXL2::MMP9::P3H2::P3H1::TLL1::COL14A1::COL18A1::COL21A1::LOXL4::COL27A1::ADAMTS3
3,R-HSA-1474228,0,1,57,138,0,Degradation of the extracellular matrix,CAPN9::MMP24::ADAMTS8::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL13A1::COL15A1::COL16A1::COL17A1::COL19A1::COL26A1::CTSV::DCN::ADAMTS16::ADAMTS18::FBN1::FBN2::FN1::HSPG2::KLKB1::LAMA3::LAMB1::LAMB3::LAMC1::LAMC2::MMP2::MMP9::MMP14::NID1::SPOCK3::KLK7::ADAMTS9::SPP1::TIMP1::TIMP2::TLL1::COL14A1::COL18A1::FBN3::CAPN13::CD44
4,R-HSA-1650814,0,1,37,67,0,Collagen biosynthesis and modifying enzymes,P3H3::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL13A1::COL15A1::COL16A1::COL17A1::COL19A1::COL26A1::ADAMTS14::COLGALT2::PCOLCE2::COL28A1::P3H2::P3H1::TLL1::COL14A1::COL18A1::COL21A1::COL27A1::ADAMTS3
5,R-HSA-2022090,0,1,35,61,0,Assembly of collagen fibrils and other multimeric structures,COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL15A1::COL17A1::CTSV::ITGA6::ITGB4::LAMA3::LAMB3::LAMC2::LOX::LOXL1::LOXL2::MMP9::TLL1::COL14A1::COL18A1::LOXL4::COL27A1
6,R-HSA-8948216,0,1,29,44,0,Collagen chain trimerization,COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL13A1::COL15A1::COL16A1::COL17A1::COL19A1::COL26A1::COL28A1::COL14A1::COL18A1::COL21A1::COL27A1
7,R-HSA-3000157,0,1,23,30,0,Laminin interactions,LAMC3::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::LAMA1::HSPG2::ITGA6::ITGA1::ITGA3::ITGB1::ITGB4::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::NID1::COL18A1
8,R-HSA-3000171,0,1,33,59,0,Non-integrin membrane-ECM interactions,LAMC3::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL11A1::FGF2::FN1::LAMA1::HSPG2::ITGA6::ITGB1::ITGB3::ITGB4::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::PRKCA::NTN4::SDC4::TGFB1::THBS1::VTN
9,R-HSA-216083,0,1,39,83,0,Integrin cell surface interactions,COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL13A1::COL16A1::FBN1::FGG::FN1::HSPG2::ICAM1::ICAM2::ITGA6::ITGA1::ITGA3::ITGA4::ITGA5::ITGB1::ITGB2::ITGB3::ITGB8::SPP1::THBS1::ICAM5::VTN::COL18A1::CD44
10,R-HSA-3000178,0,1,37,76,0,ECM proteoglycans,COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::VCAN::DCN::FN1::LAMA1::HSPG2::ITGB1::ITGB3::LAMA2::LAMA3::LAMA4::LAMB1::LAMC1::LRP4::MATN3::MUSK::SERPINE1::BGN::SPARC::TGFB1::TGFB2::TGFB3::TNR::VTN
11,R-HSA-1566948,0,1,26,45,0,Elastic fibre formation,FBN1::FBN2::EFEMP1::FN1::BMP10::EFEMP2::ITGA5::ITGB1::ITGB3::ITGB8::LOX::LOXL1::LOXL2::LTBP2::LTBP3::MFAP2::BMP2::BMP4::TGFB1::TGFB2::TGFB3::VTN::MFAP5::EMILIN2::LOXL4::FBN3
12,R-HSA-500792,0,1,104,448,0,GPCR ligand binding,CALCRL::RAMP2::RAMP1::RAMP3::CYSLTR1::CGA::NMU::UTS2::HRH3::ADCYAP1::CCR7::CMKLR1::ADM::ADORA2B::ADRA1B::ADRA2C::CX3CR1::ADRB2::DRD1::AGTR1::S1PR1::LPAR1::EDN1::EDNRB::ADGRE1::F2R::F2RL1::LPAR3::FPR1::FZD2::GABBR1::UTS2B::TAS2R46::C5AR2::P2RY10::GNG10::GNG11::GNGT2::GPR17::FFAR2::GRM3::GRM4::GRM8::CXCL1::CXCL2::CXCL3::GRPR::ANXA1::HRH1::HTR1D::HTR2C::HTR4::HCAR2::CXCL8::KISS1::MC4R::MTNR1A::NPY1R::NPY5R::NTS::P2RY1::P2RY2::GAL::WNT16::GNG2::WNT4::PLPPR1::AVPR1A::AVPR2::NPY4R::LPAR5::PTGER3::PTGFR::PTH1R::CCL17::CCL20::CXCL11::CXCL5::XCL1::CXCL12::NPFFR1::SMO::TBXA2R::C3::TRH::VIPR1::WNT3::WNT6::WNT7A::WNT11::XK::CXCR4::PLPPR3::WNT10A::FZD6::FZD7::QRFPR::CASR::HCAR3::F2RL3::CCRL2::GLP2R::ADGRE5::PLPPR4
13,R-HSA-8874081,0,1,20,30,0,MET activates PTK2 signaling,LAMC3::COL1A2::COL3A1::COL5A1::COL5A2::COL11A1::FN1::LAMA1::ITGA3::ITGB1::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::MET::SRC::COL27A1
14,R-HSA-1442490,0,1,29,62,0,Collagen degradation,COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::COL5A1::COL5A2::COL6A1::COL6A2::COL8A1::COL8A2::COL9A1::COL9A3::COL11A1::COL12A1::COL13A1::COL15A1::COL16A1::COL17A1::COL19A1::COL26A1::MMP2::MMP9::MMP14::COL14A1::COL18A1
15,R-HSA-381426,0,1,43,125,0,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),CDH2::ENAM::MSLN::FSTL3::FSTL1::MGAT4A::CSF1::VCAN::NOTUM::FBN1::FGG::FN1::PCSK9::AMBN::KLK13::GAS6::APOA1::APOE::IGFBP5::IGFBP6::IGFBP7::CCN1::IL6::KLK1::LAMB1::LAMC1::LGALS1::AMTN::MATN3::MFGE8::MELTF::MMP2::PAPPA::FAM20A::BMP4::SPP1::TIMP1::C3::SCG2::BPIFB2::EVA1A::APOL1::CHRDL1
16,R-HSA-202733,0,1,45,136,0,Cell surface interactions at the vascular wall,CEACAM5::PROCR::COL1A2::FN1::FYN::GAS6::ANGPT1::ITGA6::ITGA3::ITGA4::ITGA5::ITGB1::ITGB2::ITGB3::L1CAM::LCK::LYN::PSG8::CEACAM6::OLR1::PROS1::SLC7A10::PSG1::PSG2::PSG3::PSG4::PSG5::PSG6::PSG7::PSG9::PSG11::CD177::SDC4::SELP::SELPLG::SLC16A1::SRC::TEK::TGFB1::CAV1::TNFRSF10D::SLC7A7::SLC16A3::CD44::CD74
17,R-HSA-2129379,0,1,21,38,0,Molecules associated with elastic fibres,FBN1::FBN2::EFEMP1::FN1::BMP10::EFEMP2::ITGB1::ITGB3::ITGB8::LTBP2::LTBP3::MFAP2::BMP2::BMP4::TGFB1::TGFB2::TGFB3::VTN::MFAP5::EMILIN2::FBN3
18,R-HSA-109582,0,1,131,606,0,Hemostasis,ABCC4::TUBB3::TUBB4A::VAV3::CEACAM5::PROCR::PDPN::SERPINA3::COL1A2::CD109::KLC3::ADRA2C::DGKA::DGKB::DGKG::F2R::F3::F7::FGG::P2RX2::FLNA::FN1::ZFPM2::PIK3R5::FYN::KIF26A::GAS6::GATA3::GNA15::GNG10::GNG11::GNGT2::ANGPT1::GUCY1A2::ANXA2::EHD2::APOA1::IFNA1::TUBB2B::ITGA6::ISLR::ITGA1::ITGA3::ITGA4::ITGA5::ITGB1::ITGB2::ITGB3::KIF3C::KIF5A::KLKB1::L1CAM::LCK::LYN::ARRB1::PSG8::MYB::CEACAM6::NFE2::ATP2A3::OLR1::P2RX5::P2RY1::SERPINE1::SERPINB2::PDE1A::SERPINE2::PLA2G4A::PLAT::PLAU::PLAUR::SERPINF2::GNG2::APBB1IP::KIF1A::KIF26B::PRCP::SRGN::PRKCA::PRKCH::PRKCQ::PRKG2::PROS1::SLC7A10::PSG1::PSG2::PSG3::PSG4::PSG5::PSG6::PSG7::PSG9::PSG11::CD177::RAB27B::RAC2::SDC4::SELP::SELPLG::SELENOP::SLC8A1::SLC16A1::SPARC::SRC::TBXA2R::TEK::TFPI::TGFB1::TGFB2::TGFB3::THBS1::TIMP1::TIMP3::SERPING1::CLEC3B::TRPC3::TUBA4A::VAV1::TUBAL3::TUBB6::PIK3R3::CAV1::TNFRSF10D::F2RL3::SLC7A7::KIFC2::SLC16A3::P2RX6::CD44::GNA14::CD74
19,R-HSA-8957275,0,1,38,108,0,Post-translational protein phosphorylation,CDH2::ENAM::MSLN::FSTL3::FSTL1::MGAT4A::CSF1::VCAN::NOTUM::FBN1::FGG::FN1::PCSK9::AMBN::GAS6::APOA1::APOE::IGFBP5::IGFBP7::CCN1::IL6::LAMB1::LAMC1::LGALS1::AMTN::MATN3::MFGE8::MELTF::FAM20A::BMP4::SPP1::TIMP1::C3::SCG2::BPIFB2::EVA1A::APOL1::CHRDL1
20,R-HSA-8875878,0,1,21,41,0,MET promotes cell motility,LAMC3::COL1A2::COL3A1::COL5A1::COL5A2::COL11A1::FN1::LAMA1::ITGA3::ITGB1::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::MET::TNS3::SRC::COL27A1
21,R-HSA-373076,0,1,72,317,0,Class A 1 (Rhodopsin-like receptors),CYSLTR1::CGA::NMU::UTS2::HRH3::CCR7::CMKLR1::ADORA2B::ADRA1B::ADRA2C::CX3CR1::ADRB2::DRD1::AGTR1::S1PR1::LPAR1::EDN1::EDNRB::F2R::F2RL1::LPAR3::FPR1::UTS2B::C5AR2::P2RY10::GPR17::FFAR2::CXCL1::CXCL2::CXCL3::GRPR::ANXA1::HRH1::HTR1D::HTR2C::HTR4::HCAR2::CXCL8::KISS1::MC4R::MTNR1A::NPY1R::NPY5R::NTS::P2RY1::P2RY2::GAL::PLPPR1::AVPR1A::AVPR2::NPY4R::LPAR5::PTGER3::PTGFR::CCL17::CCL20::CXCL11::CXCL5::XCL1::CXCL12::NPFFR1::TBXA2R::C3::TRH::XK::CXCR4::PLPPR3::QRFPR::HCAR3::F2RL3::CCRL2::PLPPR4
22,R-HSA-419037,0,1,20,42,0,NCAM1 interactions,COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::GDNF::GFRA1::PRNP::CACNA1D::CACNB1::CACNB4::CACNA1I::CACNA1H
23,R-HSA-2243919,0,1,12,18,1.00E-04,Crosslinking of collagen fibrils,COL1A2::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::LOX::LOXL1::LOXL2::TLL1::LOXL4
24,R-HSA-2214320,0,1,11,15,1.00E-04,Anchoring fibril formation,COL1A2::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL4A6::LAMA3::LAMB3::LAMC2::TLL1
25,R-HSA-416476,0,1,54,214,1.00E-04,G alpha (q) signalling events,CYSLTR1::NMU::UTS2::ARHGEF25::ADRA1B::DGKA::DGKB::DGKG::HBEGF::AGTR1::LPAR1::EDN1::EDNRB::EGFR::F2R::F2RL1::LPAR3::GAST::UTS2B::P2RY10::GNA15::GNG10::GNG11::GNGT2::GPR17::FFAR2::GRPR::ANXA1::HRH1::HTR2C::KISS1::NTS::P2RY1::P2RY2::GNG2::AVPR1A::PRKCA::PRKCH::PRKCQ::LPAR5::PTGFR::RGS4::RGS16::XCL1::NPFFR1::TBXA2R::TRH::TRPC3::QRFPR::CASR::PIK3R3::KALRN::F2RL3::GNA14
26,R-HSA-397014,0,1,52,196,1.00E-04,Muscle contraction,KCNE3::ABCC9::SORBS3::MYL9::FGF13::FGF14::FKBP1B::KCNE5::LMOD1::CACNG4::TMOD2::GUCY1A2::ANXA1::ANXA2::KCNIP3::KCNIP1::ITGA1::KCND3::KCNJ2::KCNJ4::KCNJ11::MYL2::MYL3::MYL4::MYLK::NPR1::NPR2::ATP2A3::FXYD1::FXYD3::FXYD7::FXYD6::ACTA2::CACNG7::CACNG6::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::SLC8A1::TNNC1::TNNT1::TPM2::TRPC1::VIM::CACNB1::CALD1::CAMK2A::DYSF::CAV3
27,R-HSA-3000170,0,1,15,27,1.00E-04,Syndecan interactions,COL1A2::COL3A1::COL5A1::COL5A2::FGF2::FN1::ITGA6::ITGB1::ITGB3::ITGB4::PRKCA::SDC4::TGFB1::THBS1::VTN
28,R-HSA-5083635,0,1,17,36,3.00E-04,Defective B3GALTL causes Peters-plus syndrome (PpS),ADAMTS8::ADAMTS7::ADAMTS6::ADAMTS14::ADAMTS16::ADAMTS18::ADAMTS19::THSD7A::ADAMTSL4::ADAMTS9::THBS1::ADAMTS20::ADAMTS12::ADAMTS10::ADAMTSL1::ADAMTS3::ADAMTSL2
29,R-HSA-6783783,0,1,17,41,3.00E-04,Interleukin-10 signaling,CSF1::CSF2::FPR1::CXCL1::CXCL2::ICAM1::IL1A::IL6::CXCL8::IL12B::IL18::LIF::PTGS2::CCL20::TIMP1::TNFRSF1B::IL1R2
30,R-HSA-5173214,0,1,17,37,4.00E-04,O-glycosylation of TSR domain-containing proteins,ADAMTS8::ADAMTS7::ADAMTS6::ADAMTS14::ADAMTS16::ADAMTS18::ADAMTS19::THSD7A::ADAMTSL4::ADAMTS9::THBS1::ADAMTS20::ADAMTS12::ADAMTS10::ADAMTSL1::ADAMTS3::ADAMTSL2
31,R-HSA-446728,0,1,29,90,5.00E-04,Cell junction organization,CDH2::CDH3::CDH6::CDH7::CDH11::CDH13::CLDN16::COL17A1::CLDN3::FLNA::FLNC::NECTIN3::ITGA6::ITGB1::ITGB4::KRT14::LAMA3::LAMB3::LAMC2::CLDN11::CLDN18::FBLIM1::LIMS2::PVR::NECTIN4::CLDN10::CLDN8::CLDN6::CLDN1
32,R-HSA-5173105,0,1,33,109,9.00E-04,O-linked glycosylation,CHST4::B3GNT3::ST6GALNAC2::ADAMTS8::ADAMTS7::ADAMTS6::GALNT5::MUCL1::ADAMTS14::ADAMTS16::ADAMTS18::ADAMTS19::THSD7A::ST6GALNAC3::ST6GALNAC4::MUC19::GALNTL6::A4GNT::ADAMTSL4::MUC13::ADAMTS9::THBS1::MUC5B::ADAMTS20::ADAMTS12::ADAMTS10::B3GNT5::LARGE1::ADAMTSL1::B3GNT7::MUC16::ADAMTS3::ADAMTSL2
33,R-HSA-76002,0,1,59,258,0.0019,"Platelet activation, signaling and aggregation",ABCC4::VAV3::PDPN::SERPINA3::COL1A2::CD109::ADRA2C::DGKA::DGKB::DGKG::F2R::FGG::FLNA::FN1::PIK3R5::FYN::GAS6::GNA15::GNG10::GNG11::GNGT2::APOA1::ISLR::ITGB3::LCK::LYN::ARRB1::P2RY1::SERPINE1::PLA2G4A::SERPINF2::GNG2::APBB1IP::SRGN::PRKCA::PRKCH::PRKCQ::PROS1::RAB27B::RAC2::SELP::SELENOP::SPARC::SRC::TBXA2R::TGFB1::TGFB2::TGFB3::THBS1::TIMP1::TIMP3::SERPING1::CLEC3B::TRPC3::TUBA4A::VAV1::PIK3R3::F2RL3::GNA14
34,R-HSA-3906995,0,1,23,67,0.0024,Diseases associated with O-glycosylation of proteins,ADAMTS8::ADAMTS7::ADAMTS6::MUCL1::ADAMTS14::ADAMTS16::ADAMTS18::ADAMTS19::THSD7A::MUC19::ADAMTSL4::MUC13::ADAMTS9::THBS1::MUC5B::ADAMTS20::ADAMTS12::ADAMTS10::LARGE1::ADAMTSL1::MUC16::ADAMTS3::ADAMTSL2
35,R-HSA-375165,0,1,22,63,0.0027,NCAM signaling for neurite out-growth,COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::FYN::GDNF::GFRA1::PRNP::SRC::CACNA1D::CACNB1::CACNB4::CACNA1I::CACNA1H
36,R-HSA-75205,1.00E-04,1,8,13,0.0044,Dissolution of Fibrin Clot,ANXA2::SERPINE1::SERPINB2::SERPINE2::PLAT::PLAU::PLAUR::SERPINF2
37,R-HSA-162582,1.00E-04,0.9999,415,2695,0.0049,Signal Transduction,AKT3::FRAT1::CALCRL::SPRY2::RAMP2::RAMP1::RAMP3::FSTL3::LAMC3::TUBB3::TUBB4A::DLC1::MYL9::VAV3::FST::CDC42EP3::ADCY1::NRG3::IQGAP2::ADCY2::CFTR::CYSLTR1::CGA::NOXA1::NMU::UTS2::ADCY5::FSTL1::WIF1::GPR176::HRH3::ADCY7::FMNL2::RHPN1::ARHGEF25::ADCYAP1::PIK3AP1::LRRK2::SDR9C7::CCR7::CMKLR1::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::COL11A1::EVC2::ADM::ADORA2B::CRABP1::CSF2::CSF2RA::ARHGAP42::PRICKLE1::ADRA1B::NOTUM::KLC3::PLB1::ADRA2C::CX3CR1::ADRB2::ATP6V0E2::OR1Q1::ARHGAP36::AWAT2::CYP26A1::DGKA::DGKB::DGKG::OR7D2::RHOV::DIAPH2::DYNC1I1::DRD1::JAG1::HBEGF::DUSP4::AGTR1::DUSP9::S1PR1::LPAR1::EDN1::EDNRB::EGFR::SDR16C5::ELF3::ADGRE1::ESR1::MECOM::F2R::F2RL1::F3::FABP5::FGF1::FGF2::FGF5::FGFR2::FGG::MRAS::CNKSR2::DZIP1::DKK1::HECW1::PLXND1::FLNA::KANK1::FLT4::FN1::GPR161::HEY2::PIK3R5::LPAR3::FPR1::FLRT2::ATP6V0D2::NR5A2::GAST::FYN::FZD2::GABBR1::GABRA1::GABRG2::UTS2B::RASGRP3::TAS2R46::PYGO1::TIAM2::GATA3::FGF20::OR10A3::HEYL::GDNF::GFRA1::BEX3::C5AR2::BMP10::P2RY10::GLI2::GLI3::GNA15::GNG10::GNG11::GNGT2::GPR15::ANGPT1::GPR17::LAMA1::GPR20::FFAR2::GRIN1::GRM3::GRM4::GRM8::CXCL1::CXCL2::CXCL3::GRPR::LRP12::GUCY2D::SH3KBP1::ANXA1::NRG1::FOXA1::HRH1::BIRC3::HSPB1::HSPG2::APOA1::HTR1D::HTR2C::HTR4::HCAR2::OR2AG2::ID2::APOC1::APOC4::TUBB2B::APOE::IL1RAP::IL6::CXCL8::INHBA::INHBB::AR::ITGA3::ITGB1::ITGB3::KIF7::KIF5A::KISS1::OR56A3::OR5AU1::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::LCK::LEPR::RHOH::LRP1::LRP2::LYN::ARRB1::SMAD9::MC4R::MCF2::MDK::MET::MFNG::MMP2::MMP9::CITED1::ARHGEF35::MST1R::MTNR1A::MYB::MYLK::NCF2::NGF::NGFR::NPY1R::NPY5R::ATP2A3::NTF3::NTF4::ROR1::ROR2::NTS::OR1F1::P2RY1::P2RY2::SERPINE1::ARHGEF4::TRAT1::SOST::GAL::REEP2::DACT1::PDE1A::PDE1C::WNT16::PDE3A::PDE4A::EVL::PDE6B::PDGFRB::PGF::PGR::PIK3CD::PLA2G4A::PLAT::PLTP::GNG2::WNT4::NEURL1B::APBB1IP::ARHGEF38::PLPPR1::IFT57::AVPR1A::AVPR2::NPY4R::H2AJ::PRKCA::AXL::PRKCH::PRKCQ::PRKG2::PDGFC::PSMB8::LPAR5::VANGL2::PTGER3::PTGFR::RHOJ::PTH1R::ARHGAP31::PREX1::RHOU::ARHGAP22::RAC2::RAG1::ACTA2::RBP1::RBP4::BCL2::RET::RGS4::RGS16::RRAD::RXRG::BDNF::S100A8::CCL17::CCL20::CXCL11::CXCL5::XCL1::SDC4::CXCL12::GPSM3::NPFFR1::SFRP1::STRA6::HHIP::ARAP3::SGK1::SMURF2::TNS3::PLEKHG2::BMP2::SNAI2::SMO::SOX2::SOX3::SPARC::SPP1::SRC::SRMS::TBXA2R::TCF7::TEK::TFF1::TFF3::TGFA::TGFB1::TGFBR2::THBS1::TLE4::TNFAIP3::C3::TRH::TRPC3::TUBA4A::VAV1::VIPR1::WNT3::WNT6::WNT7A::WNT11::XK::CXCR4::DYNC2H1::TUBAL3::PLPPR3::WLS::PREX2::WNT10A::ADAM12::FOSL1::WNT5B::CAMK4::CAMK2A::AXIN2::FZD6::FZD7::SOX7::RTP3::PIP5K1B::QRFPR::MAML2::CASR::TUBB6::RSPO3::PIK3R3::COL27A1::SYDE1::LGR5::CDC14B::CAV1::CAV2::RGS20::TNFSF10::RGS9::TNFRSF10D::NRP2::NRP1::HCAR3::KSR1::KALRN::F2RL3::CCRL2::SH2D2A::IL33::NEURL1::DEPDC7::CHRDL1::NOG::GLP2R::KL::ARHGAP18::ACVRL1::ARHGAP29::PPP1R14A::RASAL2::ABCG1::GNA14::GREB1::HDAC9::STARD8::ADGRE5::PLPPR4::FGFBP1
38,R-HSA-2219530,1.00E-04,1,23,75,0.0063,Constitutive Signaling by Aberrant PI3K in Cancer,NRG3::PIK3AP1::HBEGF::EGFR::ESR1::FGF1::FGF2::FGF5::FGFR2::FYN::FGF20::NRG1::LCK::MET::TRAT1::PDGFRB::PIK3CD::RAC2::SRC::TGFA::VAV1::PIK3R3::KL
39,R-HSA-373080,1.00E-04,1,26,94,0.0064,Class B 2 (Secretin family receptors),CALCRL::RAMP2::RAMP1::RAMP3::ADCYAP1::ADM::ADGRE1::FZD2::GNG10::GNG11::GNGT2::WNT16::GNG2::WNT4::PTH1R::SMO::VIPR1::WNT3::WNT6::WNT7A::WNT11::WNT10A::FZD6::FZD7::GLP2R::ADGRE5
40,R-HSA-1500931,1.00E-04,0.9999,34,128,0.0071,Cell-Cell communication,CDH2::CDH3::CDH6::CDH7::CDH11::CDH13::SIRPB1::CLDN16::COL17A1::CLDN3::FLNA::FLNC::FYN::NECTIN3::ITGA6::ITGB1::ITGB4::KRT14::LAMA3::LAMB3::LAMC2::CLDN11::CLDN18::FBLIM1::KIRREL1::LIMS2::PVR::SRC::NECTIN4::KIRREL2::CLDN10::CLDN8::CLDN6::CLDN1
41,R-HSA-375276,1.00E-04,0.9999,41,187,0.0071,Peptide ligand-binding receptors,NMU::UTS2::CCR7::CX3CR1::AGTR1::EDN1::EDNRB::F2R::F2RL1::FPR1::UTS2B::C5AR2::CXCL1::CXCL2::CXCL3::GRPR::ANXA1::CXCL8::KISS1::MC4R::NPY1R::NPY5R::NTS::GAL::AVPR1A::AVPR2::NPY4R::CCL17::CCL20::CXCL11::CXCL5::XCL1::CXCL12::NPFFR1::C3::TRH::XK::CXCR4::QRFPR::F2RL3::CCRL2
42,R-HSA-6785807,1.00E-04,0.9999,29,108,0.0077,Interleukin-4 and Interleukin-13 signaling,COL1A2::S1PR1::FGF2::FN1::GATA3::ANXA1::ICAM1::IL1A::IL6::CXCL8::IL12B::IL18::ITGB1::ITGB2::LBP::LIF::MMP2::MMP9::PTGS2::RHOU::BCL2::RORC::FSCN1::SOX2::ZEB1::TGFB1::TIMP1::TNFRSF1B::VIM
43,R-HSA-373760,1.00E-04,0.9999,32,117,0.0077,L1CAM interactions,TUBB3::TUBB4A::EGFR::EPHB2::NFASC::GAP43::RPS6KA6::LAMA1::ANK2::TUBB2B::ITGA1::ITGA5::ITGB1::ITGB3::KCNQ3::L1CAM::LAMB1::LAMC1::MSN::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::SRC::TUBA4A::TUBAL3::TUBB6::CNTNAP1::NRP2::NRP1
44,R-HSA-190861,2.00E-04,1,13,34,0.0104,Gap junction assembly,GJC1::TUBB3::TUBB4A::GJB6::GJA1::GJA3::GJB2::GJB3::TUBB2B::GJC2::TUBA4A::TUBAL3::TUBB6
45,R-HSA-446107,2.00E-04,1,7,11,0.0126,Type I hemidesmosome assembly,COL17A1::ITGA6::ITGB4::KRT14::LAMA3::LAMB3::LAMC2
46,R-HSA-112316,2.00E-04,0.9999,83,407,0.0127,Neuronal System,GJC1::ABCC9::TUBB3::TUBB4A::ADCY1::ADCY2::CPLX1::CHAT::ADCY5::IL1RAPL1::ADCY7::SLITRK4::SYT9::ABAT::EPB41L2::NLGN1::RIMS1::KCNH3::GABBR1::GABRA1::GABRA3::GABRG2::GAD1::SLITRK5::CACNG4::KCNH5::NAAA::RPS6KA6::GNG10::GNG11::GNGT2::GRIK3::GRIK4::GRIN1::NRG1::TUBB2B::IL1RAP::KCNA7::KCNC4::KCND3::KCNG1::KCNJ2::KCNJ3::KCNJ4::KCNJ11::KCNJ15::KCNJ16::KCNN2::KCNN4::KCNQ3::KCNS1::KCNS3::MAPT::GNG2::PRKCA::KCNQ5::LRFN2::KIF17::DLGAP3::RAB3A::BCHE::SLC1A1::SLC1A3::SLC6A11::SRC::TUBA4A::CACNA2D1::CACNB1::CACNB4::TUBAL3::GLRA3::CAMK4::CAMK2A::NCALD::SLITRK6::TUBB6::PPFIBP2::LIN7A::SYT7::SYT12::KCNG4::KCNB2::NRXN3
47,R-HSA-8866910,3.00E-04,1,8,15,0.0133,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,CGA::EGFR::ESR1::TFAP2B::TFAP2C::TGFA::CGB5::CGB8
48,R-HSA-3295583,3.00E-04,0.9999,12,28,0.0133,TRP channels,RIPK3::TRPM6::TRPV3::MCOLN2::MCOLN3::TRPV6::TRPV5::TRPV4::TRPC1::TRPC3::TRPC4::TRPM3
49,R-HSA-2473224,3.00E-04,1,4,4,0.0149,Antagonism of Activin by Follistatin,FSTL3::FST::INHBA::INHBB
50,R-HSA-5576892,4.00E-04,0.9999,13,34,0.0204,Phase 0 - rapid depolarisation,FGF13::FGF14::CACNG4::CACNG7::CACNG6::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::CACNB1::CAMK2A
51,R-HSA-5576891,5.00E-04,0.9998,32,128,0.0223,Cardiac conduction,KCNE3::ABCC9::FGF13::FGF14::FKBP1B::KCNE5::CACNG4::KCNIP3::KCNIP1::KCND3::KCNJ2::KCNJ4::KCNJ11::NPR1::NPR2::ATP2A3::FXYD1::FXYD3::FXYD7::FXYD6::CACNG7::CACNG6::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::SLC8A1::TRPC1::CACNB1::CAMK2A
52,R-HSA-163125,5.00E-04,0.9998,23,88,0.0244,Post-translational modification- synthesis of GPI-anchored proteins,MSLN::CEACAM5::CEACAM7::NRN1L::CD109::CPM::RTN4RL1::RAET1L::ALPI::ALPG::NEGR1::GP2::LYPD5::RAET1G::LY6H::MELTF::CNTN3::PLAUR::CNTN5::THY1::PSCA::LY6G6C::RECK
53,R-HSA-9675108,5.00E-04,0.9996,104,570,0.0244,Nervous system development,SEMA3A::TUBB3::TUBB4A::MYL9::VAV3::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::CYP51A1::DCC::DPYSL3::DSCAM::EFNA3::EFNB3::EGFR::EPHA2::EPHA3::EPHA5::EPHB2::NFASC::PLXND1::FYN::GAP43::GDNF::GFRA1::RND1::RPS6KA6::LAMA1::ANK2::GRIN1::SH3KBP1::HOXA2::TUBB2B::ISL1::ITGA1::ITGA5::ITGB1::ITGB3::KCNQ3::L1CAM::LAMA2::LAMB1::LAMC1::LYN::MBP::MET::MMP2::MMP9::MSN::MYO10::EVL::PIK3CD::PRKCA::PRKCQ::PRNP::RELN::LHX9::PSMB8::NTN4::RET::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::CXCL12::ROBO3::ARHGEF28::SRC::TEAD1::TRPC1::TRPC3::TRPC4::TUBA4A::UTRN::CACNA1D::CACNB1::CACNB4::CXCR4::TUBAL3::SCD5::ABLIM2::TUBB6::SEMA7A::PIK3R3::CNTNAP1::NRP2::NRP1::CACNA1I::CACNA1H::KALRN::UNC5A::PLXNA4::SLIT2
54,R-HSA-372790,7.00E-04,0.9995,175,1128,0.0308,Signaling by GPCR,AKT3::CALCRL::RAMP2::RAMP1::RAMP3::VAV3::ADCY1::ADCY2::CYSLTR1::CGA::NMU::UTS2::ADCY5::GPR176::HRH3::ADCY7::ARHGEF25::ADCYAP1::SDR9C7::CCR7::CMKLR1::ADM::ADORA2B::ADRA1B::PLB1::ADRA2C::CX3CR1::ADRB2::OR1Q1::AWAT2::DGKA::DGKB::DGKG::OR7D2::DRD1::HBEGF::AGTR1::S1PR1::LPAR1::EDN1::EDNRB::EGFR::ADGRE1::F2R::F2RL1::PIK3R5::LPAR3::FPR1::GAST::FZD2::GABBR1::UTS2B::TAS2R46::TIAM2::OR10A3::C5AR2::P2RY10::GNA15::GNG10::GNG11::GNGT2::GPR15::GPR17::GPR20::FFAR2::GRM3::GRM4::GRM8::CXCL1::CXCL2::CXCL3::GRPR::LRP12::GUCY2D::ANXA1::HRH1::HSPG2::APOA1::HTR1D::HTR2C::HTR4::HCAR2::OR2AG2::APOE::CXCL8::KISS1::OR56A3::OR5AU1::LRP1::LRP2::ARRB1::MC4R::MCF2::ARHGEF35::MTNR1A::NPY1R::NPY5R::NTS::OR1F1::P2RY1::P2RY2::ARHGEF4::GAL::REEP2::PDE1A::PDE1C::WNT16::PDE3A::PDE4A::PDE6B::PLA2G4A::GNG2::WNT4::ARHGEF38::PLPPR1::AVPR1A::AVPR2::NPY4R::PRKCA::PRKCH::PRKCQ::LPAR5::PTGER3::PTGFR::PTH1R::PREX1::RBP1::RBP4::RGS4::RGS16::CCL17::CCL20::CXCL11::CXCL5::XCL1::SDC4::CXCL12::GPSM3::NPFFR1::STRA6::PLEKHG2::SMO::SRC::TBXA2R::C3::TRH::TRPC3::VAV1::VIPR1::WNT3::WNT6::WNT7A::WNT11::XK::CXCR4::PLPPR3::WNT10A::CAMK4::CAMK2A::FZD6::FZD7::RTP3::QRFPR::CASR::PIK3R3::RGS20::RGS9::HCAR3::KALRN::F2RL3::CCRL2::GLP2R::GNA14::ADGRE5::PLPPR4
55,R-HSA-157858,7.00E-04,0.9998,15,47,0.0321,Gap junction trafficking and regulation,GJC1::TUBB3::TUBB4A::GJB6::DAB2::GJA1::GJA3::GJB2::GJB3::TUBB2B::GJC2::SRC::TUBA4A::TUBAL3::TUBB6
56,R-HSA-209968,8.00E-04,0.9999,6,10,0.0327,Thyroxine biosynthesis,CGA::DIO1::IYD::DUOX2::DUOX1::TPO
57,R-HSA-8864260,8.00E-04,0.9998,13,38,0.0332,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,CGA::CITED4::EGFR::ESR1::APOE::CITED1::PITX2::TFAP2B::TFAP2C::TGFA::KCTD15::CGB5::CGB8
58,R-HSA-2672351,8.00E-04,0.9996,28,108,0.0332,Stimuli-sensing channels,RIPK3::CLCN4::CLCNKB::SLC9B2::TRPM6::TRPV3::TSC22D3::ANO5::FKBP1B::MCOLN2::NALCN::UNC80::ANO1::MCOLN3::TRPV6::TRPV5::TRPV4::SCNN1B::SGK1::WNK4::WNK3::TRPC1::TRPC3::TRPC4::TRPM3::ASIC3::TTYH2::CLCA2
59,R-HSA-418597,0.001,0.9997,15,47,0.0382,G alpha (z) signalling events,ADCY1::ADCY2::ADCY5::ADCY7::ADRA2C::GNG10::GNG11::GNGT2::GNG2::PRKCA::PRKCH::PRKCQ::RGS4::RGS16::RGS20
60,R-HSA-190872,0.001,0.9998,8,18,0.0389,Transport of connexons to the plasma membrane,TUBB3::TUBB4A::GJA1::GJB2::TUBB2B::TUBA4A::TUBAL3::TUBB6
61,R-HSA-186797,0.001,0.9997,18,58,0.0389,Signaling by PDGF,COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::PDGFRB::PLAT::PDGFC::SPP1::SRC::THBS1
62,R-HSA-6811558,0.001,0.9996,26,102,0.0389,"PI5P, PP2A and IER3 Regulate PI3K AKT Signaling",NRG3::PIK3AP1::HBEGF::EGFR::ESR1::FGF1::FGF2::FGF5::FGFR2::FYN::FGF20::NRG1::IL1RAP::LCK::MET::TRAT1::PDGFRB::PIK3CD::RAC2::SRC::TGFA::VAV1::PIP5K1B::PIK3R3::IL33::KL
63,R-HSA-418594,0.001,0.9994,72,388,0.0392,G alpha (i) signalling events,ADCY1::ADCY2::NMU::ADCY5::ADCY7::SDR9C7::CCR7::PLB1::ADRA2C::CX3CR1::AWAT2::LPAR1::LPAR3::FPR1::GABBR1::TAS2R46::GNG10::GNG11::GNGT2::GPR17::GRM3::GRM4::GRM8::CXCL1::CXCL2::CXCL3::LRP12::GUCY2D::ANXA1::HSPG2::APOA1::HTR1D::HCAR2::APOE::CXCL8::LRP1::LRP2::MTNR1A::NPY1R::NPY5R::GAL::PDE1A::PDE1C::PDE4A::PDE6B::PLA2G4A::GNG2::NPY4R::PRKCA::PRKCQ::LPAR5::PTGER3::RBP1::RBP4::RGS4::RGS16::CCL20::CXCL11::CXCL5::SDC4::CXCL12::GPSM3::STRA6::SRC::C3::CXCR4::CAMK4::CAMK2A::CASR::RGS20::RGS9::HCAR3
64,R-HSA-209776,0.0011,0.9998,8,18,0.0398,Metabolism of amine-derived hormones,CGA::DDC::DIO1::IYD::ASMT::DUOX2::DUOX1::TPO
65,R-HSA-422475,0.0011,0.9993,98,545,0.0402,Axon guidance,SEMA3A::TUBB3::TUBB4A::MYL9::VAV3::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::DCC::DPYSL3::DSCAM::EFNA3::EFNB3::EGFR::EPHA2::EPHA3::EPHA5::EPHB2::NFASC::PLXND1::FYN::GAP43::GDNF::GFRA1::RND1::RPS6KA6::LAMA1::ANK2::GRIN1::SH3KBP1::HOXA2::TUBB2B::ISL1::ITGA1::ITGA5::ITGB1::ITGB3::KCNQ3::L1CAM::LAMB1::LAMC1::LYN::MET::MMP2::MMP9::MSN::MYO10::EVL::PIK3CD::PRKCA::PRKCQ::PRNP::RELN::LHX9::PSMB8::NTN4::RET::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::CXCL12::ROBO3::ARHGEF28::SRC::TRPC1::TRPC3::TRPC4::TUBA4A::CACNA1D::CACNB1::CACNB4::CXCR4::TUBAL3::ABLIM2::TUBB6::SEMA7A::PIK3R3::CNTNAP1::NRP2::NRP1::CACNA1I::CACNA1H::KALRN::UNC5A::PLXNA4::SLIT2
66,R-HSA-3781865,0.0011,0.9994,34,142,0.0402,Diseases of glycosylation,KERA::ADAMTS8::ADAMTS7::ADAMTS6::MUCL1::ADAMTS14::VCAN::CSPG4::DCN::ADAMTS16::ADAMTS18::ADAMTS19::SLC26A2::EXT1::THSD7A::MUC19::HSPG2::ADAMTSL4::PRELP::MUC13::ADAMTS9::BGN::SDC4::THBS1::MUC5B::ADAMTS20::ADAMTS12::ADAMTS10::LARGE1::ADAMTSL1::MUC16::CHST3::ADAMTS3::ADAMTSL2
67,R-HSA-977444,0.0012,0.9997,14,43,0.0402,GABA B receptor activation,ADCY1::ADCY2::ADCY5::ADCY7::GABBR1::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::GNG2
68,R-HSA-991365,0.0012,0.9997,14,43,0.0402,Activation of GABAB receptors,ADCY1::ADCY2::ADCY5::ADCY7::GABBR1::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::GNG2
69,R-HSA-6806834,0.0012,0.9995,22,79,0.0421,Signaling by MET,LAMC3::COL1A2::COL3A1::COL5A1::COL5A2::COL11A1::FN1::LAMA1::SH3KBP1::ITGA3::ITGB1::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::MET::TNS3::SRC::COL27A1
70,R-HSA-1296065,0.0013,0.9997,12,35,0.0435,Inwardly rectifying K+ channels,ABCC9::GABBR1::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ11::KCNJ15::KCNJ16::GNG2
71,R-HSA-190828,0.0014,0.9996,14,45,0.0444,Gap junction trafficking,GJC1::TUBB3::TUBB4A::GJB6::DAB2::GJA1::GJA3::GJB2::GJB3::TUBB2B::GJC2::TUBA4A::TUBAL3::TUBB6
72,R-HSA-199418,0.0014,0.9994,27,109,0.0444,Negative regulation of the PI3K AKT network,AKT3::NRG3::PIK3AP1::HBEGF::EGFR::ESR1::FGF1::FGF2::FGF5::FGFR2::FYN::FGF20::NRG1::IL1RAP::LCK::MET::TRAT1::PDGFRB::PIK3CD::RAC2::SRC::TGFA::VAV1::PIP5K1B::PIK3R3::IL33::KL
73,R-HSA-1296071,0.0014,0.9994,26,103,0.0444,Potassium Channels,ABCC9::KCNH3::GABBR1::KCNH5::GNG10::GNG11::GNGT2::KCNA7::KCNC4::KCND3::KCNG1::KCNJ2::KCNJ3::KCNJ4::KCNJ11::KCNJ15::KCNJ16::KCNN2::KCNN4::KCNQ3::KCNS1::KCNS3::GNG2::KCNQ5::KCNG4::KCNB2
74,R-HSA-983712,0.0014,0.9993,41,185,0.0444,Ion channel transport,RIPK3::CLCN4::CLCNKB::SLC9B2::TRPM6::ATP8B3::ATP6V0E2::TRPV3::TSC22D3::ANO5::FKBP1B::ATP6V0D2::MCOLN2::NALCN::UNC80::ATP13A5::ATP2A3::FXYD1::FXYD3::FXYD7::FXYD6::ANO1::MCOLN3::TRPV6::TRPV5::ATP10D::TRPV4::SCNN1B::SGK1::WNK4::WNK3::TRPC1::TRPC3::TRPC4::TRPM3::CAMK2A::ATP13A4::ASIC3::TTYH2::CLCA2::ATP2C2
75,R-HSA-445355,0.0014,0.9996,13,40,0.0444,Smooth Muscle Contraction,SORBS3::MYL9::LMOD1::GUCY1A2::ANXA1::ANXA2::ITGA1::MYLK::ACTA2::TPM2::CALD1::DYSF::CAV3
76,R-HSA-419408,0.0014,0.9998,7,14,0.0444,Lysosphingolipid and LPA receptors,S1PR1::LPAR1::LPAR3::PLPPR1::LPAR5::PLPPR3::PLPPR4
77,R-HSA-977443,0.0019,0.9993,17,59,0.0577,GABA receptor activation,ADCY1::ADCY2::ADCY5::ADCY7::GABBR1::GABRA1::GABRA3::GABRG2::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::GNG2
78,R-HSA-2022923,0.0022,0.9998,6,11,0.0655,Dermatan sulfate biosynthesis,VCAN::CSPG4::DCN::DSE::BGN::DSEL
79,R-HSA-3595172,0.0024,0.9998,5,8,0.0706,Defective CHST3 causes SEDCJD,VCAN::CSPG4::DCN::BGN::CHST3
80,R-HSA-140877,0.0025,0.9993,12,38,0.0725,Formation of Fibrin Clot (Clotting Cascade),PROCR::F2R::F3::F7::FGG::KLKB1::SERPINE2::PRCP::PROS1::CD177::TFPI::SERPING1
81,R-HSA-380108,0.0025,0.9992,14,52,0.0725,Chemokine receptors bind chemokines,CCR7::CX3CR1::CXCL1::CXCL2::CXCL3::CXCL8::CCL17::CCL20::CXCL11::CXCL5::XCL1::CXCL12::CXCR4::CCRL2
82,R-HSA-1280215,0.0027,0.998,142,858,0.0757,Cytokine Signaling in Immune system,TRIM10::EBI3::IFITM2::TRIM3::NRG3::IL1RAPL1::IRAK3::GBP5::CISH::IL22RA2::CNN2::CNTFR::COL1A2::IL31RA::CSF1::CSF2::CSF2RA::CTF1::IFNLR1::HBEGF::DUSP4::DUSP9::S1PR1::EGFR::FGF1::FGF2::FGF5::FGFR2::FGG::MRAS::CNKSR2::FLNA::FN1::CLCF1::FPR1::TRIM29::IFIT5::IL27::FYN::RASGRP3::GATA3::FGF20::GBP1::GDNF::GFRA1::GHR::ANGPT1::GRIN1::CXCL1::CXCL2::BLNK::ANXA1::ANXA2::NRG1::HLA-A::HLA-B::HLA-DQA1::BIRC3::ICAM1::IFIT2::IFIT1::IFIT3::IFNA1::IL1A::IL1RAP::IL6::IL7R::CXCL8::IL12B::IL12RB2::TNFRSF9::IL18::IRAK2::IRF7::ITGB1::ITGB2::ITGB3::LBP::LCK::LIF::LTB::LYN::ARRB1::MET::MID1::MMP2::MMP9::MSN::MX2::TNFRSF11B::SERPINB2::IL20::PDGFRB::PIK3CD::APBB1IP::PRKCQ::PRKG2::MAPK10::PRL::PRLR::PSMB8::PTGS2::RHOU::RAG1::IL22RA1::BCL2::RET::RNASEL::RORC::S100A12::CCL20::CRLF2::FSCN1::SOX2::SRC::BST2::ZEB1::TEK::TGFA::TGFB1::TIMP1::TNFRSF1B::VAV1::VIM::IL1R2::TRIM48::CAMK2A::PIK3R3::TNFSF14::TNFSF12::TNFRSF14::IL1RL2::KSR1::TNFSF18::IL33::OSMR::IL32::KL::RASAL2::CD40::CD44::TNFSF15
83,R-HSA-1296041,0.0027,0.9993,10,29,0.0757,Activation of G protein gated Potassium channels,GABBR1::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::GNG2
84,R-HSA-1296059,0.0027,0.9993,10,29,0.0757,G protein gated Potassium channels,GABBR1::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::GNG2
85,R-HSA-997272,0.0027,0.9993,10,29,0.0757,Inhibition  of voltage gated Ca2+ channels via Gbeta gamma subunits,GABBR1::GNG10::GNG11::GNGT2::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::GNG2
86,R-HSA-418592,0.0029,0.9993,9,25,0.079,ADP signalling through P2Y purinoceptor 1,GNA15::GNG10::GNG11::GNGT2::P2RY1::PLA2G4A::GNG2::SRC::GNA14
87,R-HSA-2142770,0.003,0.9998,4,6,0.0827,Synthesis of 15-eicosatetraenoic acid derivatives,ALOX15B::GPX1::GPX2::PTGS2
88,R-HSA-190840,0.0034,0.9994,7,17,0.0921,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,TUBB3::TUBB4A::GJA1::TUBB2B::TUBA4A::TUBAL3::TUBB6
89,R-HSA-8964058,0.0036,0.9996,5,10,0.0959,HDL remodeling,APOA1::APOE::PLTP::LIPG::ABCG1
90,R-HSA-9660821,0.0037,0.9982,28,132,0.0979,ADORA2B mediated anti-inflammatory cytokines production,CALCRL::RAMP2::RAMP1::RAMP3::ADCY1::ADCY2::CGA::ADCY5::GPR176::ADCY7::ADCYAP1::ADM::ADORA2B::ADRB2::DRD1::GNG10::GNG11::GNGT2::GPR15::GPR20::HTR4::IL6::MC4R::GNG2::AVPR2::PTH1R::VIPR1::GLP2R
91,R-HSA-421270,0.0042,0.9983,17,63,0.1101,Cell-cell junction organization,CDH2::CDH3::CDH6::CDH7::CDH11::CDH13::CLDN16::CLDN3::NECTIN3::CLDN11::CLDN18::PVR::NECTIN4::CLDN10::CLDN8::CLDN6::CLDN1
92,R-HSA-2022870,0.0043,0.9991,8,20,0.1118,Chondroitin sulfate biosynthesis,VCAN::CSPG4::DCN::CHST13::CHSY3::CHST7::BGN::CHST3
93,R-HSA-9006934,0.0044,0.9969,91,504,0.1126,Signaling by Receptor Tyrosine Kinases,AKT3::SPRY2::LAMC3::VAV3::NRG3::ADCYAP1::COL1A2::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::COL11A1::ATP6V0E2::HBEGF::DUSP4::EGFR::ESR1::F3::FGF1::FGF2::FGF5::FGFR2::FLT4::FN1::FLRT2::ATP6V0D2::FYN::GABRA1::GABRG2::FGF20::LAMA1::SH3KBP1::NRG1::HSPB1::ID2::APOE::ITGA3::ITGB1::ITGB3::LAMA2::LAMA3::LAMA4::LAMB1::LAMB3::LAMC1::LAMC2::LCK::LYN::MET::MMP9::MST1R::NCF2::NGF::NTF3::NTF4::PDGFRB::PGF::PGR::PLAT::PRKCA::AXL::PDGFC::RRAD::BDNF::CXCL12::SGK1::TNS3::SPARC::SPP1::SRC::TGFA::THBS1::VAV1::ADAM12::FOSL1::PIK3R3::COL27A1::CAV1::NRP2::NRP1::SH2D2A::KL::FGFBP1
94,R-HSA-2219528,0.0045,0.9979,24,101,0.1126,PI3K AKT Signaling in Cancer,AKT3::NRG3::PIK3AP1::HBEGF::EGFR::ESR1::FGF1::FGF2::FGF5::FGFR2::FYN::FGF20::NRG1::LCK::MET::TRAT1::PDGFRB::PIK3CD::RAC2::SRC::TGFA::VAV1::PIK3R3::KL
95,R-HSA-1566977,0.0047,0.9997,4,6,0.1157,Fibronectin matrix formation,FN1::ITGA5::ITGB1::CEACAM6
96,R-HSA-419812,0.0047,0.9995,5,10,0.1157,Calcitonin-like ligand receptors,CALCRL::RAMP2::RAMP1::RAMP3::ADM
97,R-HSA-3238698,0.0051,0.9987,9,26,0.1232,WNT ligand biogenesis and trafficking,WNT16::WNT4::WNT3::WNT6::WNT7A::WNT11::WLS::WNT10A::WNT5B
98,R-HSA-210991,0.0052,0.9987,9,25,0.1267,Basigin interactions,ITGA6::ITGA3::ITGB1::L1CAM::SLC7A10::SLC16A1::CAV1::SLC7A7::SLC16A3
99,R-HSA-5686938,0.0057,0.9988,7,19,0.1373,Regulation of TLR by endogenous ligand,TLR6::FGG::LBP::S100A1::S100A8::TLR1::TLR2
100,R-HSA-456926,0.006,0.9983,10,32,0.1417,Thrombin signalling through proteinase activated receptors (PARs),F2R::GNA15::GNG10::GNG11::GNGT2::ARRB1::GNG2::SRC::F2RL3::GNA14
101,R-HSA-1592389,0.0061,0.9983,10,32,0.1417,Activation of Matrix Metalloproteinases,MMP24::CTSV::KLKB1::MMP2::MMP9::MMP14::SPOCK3::TIMP1::TIMP2::COL18A1
102,R-HSA-9662851,0.0073,0.9959,33,167,0.1681,Anti-inflammatory response favouring Leishmania parasite infection,CALCRL::RAMP2::RAMP1::RAMP3::ADCY1::ADCY2::CYSLTR1::CGA::ADCY5::GPR176::ADCY7::ADCYAP1::ADM::ADORA2B::ADRB2::DRD1::FYN::GGT1::GNG10::GNG11::GNGT2::GPR15::GPR20::HTR4::IL6::LYN::MC4R::GNG2::AVPR2::PTH1R::SRC::VIPR1::GLP2R
103,R-HSA-9664433,0.0073,0.9959,33,167,0.1681,Leishmania parasite growth and survival,CALCRL::RAMP2::RAMP1::RAMP3::ADCY1::ADCY2::CYSLTR1::CGA::ADCY5::GPR176::ADCY7::ADCYAP1::ADM::ADORA2B::ADRB2::DRD1::FYN::GGT1::GNG10::GNG11::GNGT2::GPR15::GPR20::HTR4::IL6::LYN::MC4R::GNG2::AVPR2::PTH1R::SRC::VIPR1::GLP2R
104,R-HSA-2142753,0.0075,0.9971,15,58,0.1681,Arachidonic acid metabolism,CYP4F8::CYP2U1::CYP4F22::CYP1A2::CYP4B1::FAAH2::FAAH::ALOX15B::GGT1::GPX1::GPX2::PLA2G4A::PON3::PTGIS::PTGS2
105,R-HSA-209822,0.0075,0.9989,5,12,0.1681,Glycoprotein hormones,CGA::INHBA::INHBB::CGB5::CGB8
106,R-HSA-112315,0.0076,0.9952,52,267,0.1681,Transmission across Chemical Synapses,TUBB3::TUBB4A::ADCY1::ADCY2::CPLX1::CHAT::ADCY5::ADCY7::ABAT::RIMS1::GABBR1::GABRA1::GABRA3::GABRG2::GAD1::CACNG4::NAAA::RPS6KA6::GNG10::GNG11::GNGT2::GRIK3::GRIK4::GRIN1::NRG1::TUBB2B::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::MAPT::GNG2::PRKCA::KIF17::RAB3A::BCHE::SLC1A1::SLC1A3::SLC6A11::SRC::TUBA4A::CACNA2D1::CACNB1::CACNB4::TUBAL3::GLRA3::CAMK4::CAMK2A::NCALD::TUBB6::LIN7A
107,R-HSA-392518,0.0076,0.9977,10,33,0.1681,Signal amplification,GNA15::GNG10::GNG11::GNGT2::P2RY1::PLA2G4A::GNG2::SRC::TBXA2R::GNA14
108,R-HSA-71288,0.0088,0.9987,5,11,0.1938,Creatine metabolism,CKB::CKM::CKMT1B::CKMT1A::SLC6A11
109,R-HSA-382551,0.0093,0.9931,121,724,0.2018,Transport of small molecules,ABCC9::ABCC4::SLC9A6::SLCO1B1::ADCY1::ADCY2::CFTR::RIPK3::ADCY5::ADCY7::CYGB::CLCN4::CLCNKB::ADD2::ADD3::SLC9B2::TRPM6::SLC2A14::ATP8B3::SLC2A12::ATP6V0E2::SLC5A8::TRPV3::TSC22D3::SLC26A2::ANO5::DMTN::FKBP1B::ATP6V0D2::MCOLN2::PCSK9::NALCN::ABCA12::STEAP2::GNG10::GNG11::GNGT2::SLCO1B3::UNC80::SLC9A9::MICU3::SLC27A6::HBA1::APOA1::APOC1::ATP13A5::APOC4::APOE::NIPAL4::AQP1::AQP5::AQP9::KCNJ11::MB::ATP2A3::SLC22A17::PIP::FXYD1::FXYD3::PLTP::FXYD7::FXYD6::GNG2::ANO1::SLC6A15::SLC47A1::MCOLN3::SLC22A15::AVPR2::TRPV6::APOBR::AZGP1::SLC7A10::TRPV5::PSMB8::RHBG::ATP10D::SLC4A10::SLC24A3::SLC12A5::TRPV4::SCNN1B::ABCG4::SGK1::SLC1A1::SLC1A3::SLC1A4::SLC2A3::WNK4::WNK3::SLC6A11::SLC8A1::SLC11A1::SLC12A1::SLC15A1::SLC16A1::SLCO2A1::SLCO1A2::TRPC1::TRPC3::TRPC4::TRPM3::CUBN::SLC44A4::SLC2A10::CAMK2A::AMN::ATP13A4::ABCC11::SLC4A4::SLC7A7::SLC16A3::SLC16A7::SLC38A5::ASIC3::LIPG::TTYH2::ABCG2::ABCG1::CLCA2::ATP2C2
110,R-HSA-76005,0.0096,0.9949,28,133,0.207,Response to elevated platelet cytosolic Ca2+,ABCC4::SERPINA3::CD109::FGG::FLNA::FN1::GAS6::APOA1::ISLR::ITGB3::SERPINE1::SERPINF2::SRGN::PRKCA::PROS1::RAB27B::SELP::SELENOP::SPARC::TGFB1::TGFB2::TGFB3::THBS1::TIMP1::TIMP3::SERPING1::CLEC3B::TUBA4A
111,R-HSA-5576893,0.0103,0.998,6,15,0.2184,Phase 2 - plateau phase,KCNE3::KCNE5::CACNG4::CACNG7::CACNG6::CACNB1
112,R-HSA-114608,0.0103,0.9945,27,128,0.2184,Platelet degranulation ,ABCC4::SERPINA3::CD109::FGG::FLNA::FN1::GAS6::APOA1::ISLR::ITGB3::SERPINE1::SERPINF2::SRGN::PROS1::RAB27B::SELP::SELENOP::SPARC::TGFB1::TGFB2::TGFB3::THBS1::TIMP1::TIMP3::SERPING1::CLEC3B::TUBA4A
113,R-HSA-445095,0.011,0.9966,10,31,0.2302,Interaction between L1 and Ankyrins,NFASC::ANK2::KCNQ3::L1CAM::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A
114,R-HSA-8941237,0.0115,0.9995,3,4,0.2392,Invadopodia formation,ADAM12::ADAM19::SH3PXD2A
115,R-HSA-2168880,0.0124,0.9979,5,13,0.256,Scavenging of heme from plasma,HBA1::HPX::APOA1::LRP1::APOL1
116,R-HSA-114604,0.0127,0.9959,10,34,0.2584,GPVI-mediated activation cascade,VAV3::PDPN::COL1A2::PIK3R5::FYN::LCK::LYN::RAC2::VAV1::PIK3R3
117,R-HSA-449147,0.0131,0.9908,75,443,0.2643,Signaling by Interleukins,EBI3::IL1RAPL1::IRAK3::CISH::IL22RA2::CNN2::CNTFR::COL1A2::IL31RA::CSF1::CSF2::CSF2RA::CTF1::IFNLR1::DUSP4::S1PR1::FGF2::FN1::CLCF1::FPR1::IL27::FYN::GATA3::CXCL1::CXCL2::BLNK::ANXA1::ANXA2::ICAM1::IL1A::IL1RAP::IL6::IL7R::CXCL8::IL12B::IL12RB2::IL18::IRAK2::ITGB1::ITGB2::LBP::LCK::LIF::LYN::MMP2::MMP9::MSN::SERPINB2::IL20::PIK3CD::MAPK10::PSMB8::PTGS2::RHOU::RAG1::IL22RA1::BCL2::RORC::S100A12::CCL20::CRLF2::FSCN1::SOX2::ZEB1::TGFB1::TIMP1::TNFRSF1B::VAV1::VIM::IL1R2::PIK3R3::IL1RL2::IL33::OSMR::IL32
118,R-HSA-6809371,0.0132,0.993,25,129,0.2644,Formation of the cornified envelope,KLK8::KRT80::DSG4::DSG1::DSG3::FLG::CASP14::KLK5::KLK13::KRT79::LIPM::KRT2::KRT4::KRT14::KRT17::KRT32::KRT33B::KRT34::KRT81::KRT83::KRT85::SPINK6::KLK14::PKP2::SPRR2D
119,R-HSA-977068,0.0133,0.9964,8,24,0.2647,Termination of O-glycan biosynthesis,ST6GALNAC2::MUCL1::ST6GALNAC3::ST6GALNAC4::MUC19::MUC13::MUC5B::MUC16
120,R-HSA-210990,0.0139,0.9978,5,11,0.2744,PECAM1 interactions,FYN::ITGB3::LCK::LYN::SRC
121,R-HSA-2173782,0.0153,0.9945,11,42,0.2997,Binding and Uptake of Ligands by Scavenger Receptors,COL1A2::COL3A1::COL4A1::COL4A2::HBA1::HPX::APOA1::APOE::LRP1::SPARC::APOL1
122,R-HSA-1296072,0.0158,0.994,12,43,0.3056,Voltage gated Potassium channels,KCNH3::KCNH5::KCNA7::KCNC4::KCND3::KCNG1::KCNQ3::KCNS1::KCNS3::KCNQ5::KCNG4::KCNB2
123,R-HSA-1482922,0.016,0.9965,6,17,0.3078,Acyl chain remodelling of PI,PLA2R1::PLA2G4F::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5
124,R-HSA-205017,0.0164,1,2,2,0.3121,NFG and proNGF binds to p75NTR,NGF::NGFR
125,R-HSA-8941332,0.0167,0.9979,4,8,0.3139,RUNX2 regulates genes involved in cell migration,AKT3::ITGA5::RUNX2::ITGBL1
126,R-HSA-190375,0.0167,0.997,5,13,0.3139,FGFR2c ligand binding and activation,FGF1::FGF2::FGF5::FGFR2::FGF20
127,R-HSA-3595174,0.0173,0.9978,4,8,0.3218,"Defective CHST14 causes EDS, musculocontractural type",VCAN::CSPG4::DCN::BGN
128,R-HSA-209952,0.0174,0.9967,5,14,0.3218,Peptide hormone biosynthesis,CGA::INHBA::INHBB::CGB5::CGB8
129,R-HSA-3595177,0.0182,0.9977,4,8,0.3339,Defective CHSY1 causes TPBS,VCAN::CSPG4::DCN::BGN
130,R-HSA-8964011,0.0188,0.9986,3,5,0.342,HDL clearance,APOA1::CUBN::AMN
131,R-HSA-6803157,0.0191,0.9911,16,89,0.3448,Antimicrobial peptides,PGLYRP2::BPIFB6::BPIFA2::S100A7A::DEFB132::ART1::PLA2G2A::PRSS3::S100A7::S100A8::SLC11A1::TLR1::TLR2::BPIFB2::CAMP::BPIFB1
132,R-HSA-1266738,0.0195,0.9845,162,1071,0.3473,Developmental Biology,CDH2::AKT3::SEMA3A::TUBB3::TUBB4A::MYL9::VAV3::CEBPA::KLK8::COL3A1::COL4A1::COL4A2::COL4A3::COL4A4::COL4A5::COL5A1::COL5A2::COL6A1::COL6A2::COL9A1::COL9A3::KRT80::DSG4::CYP51A1::DCC::LGI4::ZNF467::DPYSL3::DSCAM::DSG1::DSG3::EFNA3::EFNB3::EGFR::EPHA2::EPHA3::EPHA5::EPHB2::FABP4::FGF2::NFASC::FLG::PLXND1::CASP14::NR5A2::FYN::KLK5::GAP43::KLK13::GDNF::GFRA1::CACNG4::RND1::RPS6KA6::LAMA1::ANK2::GRIN1::SH3KBP1::FOXA3::HNF4A::HOXA1::HOXA2::HOXA3::HOXB4::KRT79::LIPM::TUBB2B::ISL1::ITGA1::ITGA5::ITGB1::ITGB3::KCNQ3::KRT2::KRT4::KRT14::KRT17::KRT32::KRT33B::KRT34::KRT81::KRT83::KRT85::L1CAM::LAMA2::LAMB1::LAMC1::SPINK6::LYN::MBP::MET::MMP2::MMP9::KLK14::MSN::MYB::MYO10::NKX2-2::EVL::PIK3CD::PKP2::H2AJ::PRKCA::PRKCQ::PRNP::RELN::LHX9::PSMB8::NTN4::RET::SCN1B::SCN2A::SCN3A::SCN5A::SCN8A::SCN9A::CXCL12::ROBO3::ARHGEF28::SOX2::SPRR2D::SRC::TAL1::TCF4::TEAD1::NR2F2::TGFB1::TRPC1::TRPC3::TRPC4::TUBA4A::KRTAP4-8::KRTAP2-3::UTRN::ZIC3::CACNA1D::CACNB1::CACNB4::CXCR4::TUBAL3::SCD5::KRTAP1-5::KRTAP3-1::MAML2::ABLIM2::TUBB6::SEMA7A::AJUBA::PIK3R3::CNTNAP1::KRTAP4-1::KRTAP2-4::NRP2::NRP1::CACNA1I::CACNA1H::KALRN::UNC5A::PLXNA4::SLIT2::ADIPOQ::MAFB
133,R-HSA-1482801,0.0195,0.9948,7,22,0.3473,Acyl chain remodelling of PS,OSBPL5::PLA2R1::PLA2G4F::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5
134,R-HSA-6799990,0.0197,0.9983,3,6,0.3482,Metal sequestration by antimicrobial proteins,S100A7A::S100A7::S100A8
135,R-HSA-6788467,0.0203,0.9953,6,17,0.3561,IL-6-type cytokine receptor ligand interactions,CNTFR::IL31RA::CTF1::CLCF1::LIF::OSMR
136,R-HSA-3642279,0.0207,1,2,2,0.3606,TGFBR2 MSI Frameshift Mutants in Cancer,TGFB1::TGFBR2
137,R-HSA-5678420,0.0214,1,2,2,0.3668,"Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome",ABCC9::KCNJ11
138,R-HSA-140834,0.0214,0.9984,3,5,0.3668,Extrinsic Pathway of Fibrin Clot Formation,F3::F7::TFPI
139,R-HSA-388396,0.0217,0.9828,152,1057,0.3672,GPCR downstream signalling,AKT3::CALCRL::RAMP2::RAMP1::RAMP3::VAV3::ADCY1::ADCY2::CYSLTR1::CGA::NMU::UTS2::ADCY5::GPR176::ADCY7::ARHGEF25::ADCYAP1::SDR9C7::CCR7::ADM::ADORA2B::ADRA1B::PLB1::ADRA2C::CX3CR1::ADRB2::OR1Q1::AWAT2::DGKA::DGKB::DGKG::OR7D2::DRD1::HBEGF::AGTR1::LPAR1::EDN1::EDNRB::EGFR::F2R::F2RL1::PIK3R5::LPAR3::FPR1::GAST::GABBR1::UTS2B::TAS2R46::TIAM2::OR10A3::P2RY10::GNA15::GNG10::GNG11::GNGT2::GPR15::GPR17::GPR20::FFAR2::GRM3::GRM4::GRM8::CXCL1::CXCL2::CXCL3::GRPR::LRP12::GUCY2D::ANXA1::HRH1::HSPG2::APOA1::HTR1D::HTR2C::HTR4::HCAR2::OR2AG2::APOE::CXCL8::KISS1::OR56A3::OR5AU1::LRP1::LRP2::ARRB1::MC4R::MCF2::ARHGEF35::MTNR1A::NPY1R::NPY5R::NTS::OR1F1::P2RY1::P2RY2::ARHGEF4::GAL::REEP2::PDE1A::PDE1C::PDE3A::PDE4A::PDE6B::PLA2G4A::GNG2::ARHGEF38::AVPR1A::AVPR2::NPY4R::PRKCA::PRKCH::PRKCQ::LPAR5::PTGER3::PTGFR::PTH1R::PREX1::RBP1::RBP4::RGS4::RGS16::CCL20::CXCL11::CXCL5::XCL1::SDC4::CXCL12::GPSM3::NPFFR1::STRA6::PLEKHG2::SRC::TBXA2R::C3::TRH::TRPC3::VAV1::VIPR1::CXCR4::CAMK4::CAMK2A::RTP3::QRFPR::CASR::PIK3R3::RGS20::RGS9::HCAR3::KALRN::F2RL3::GLP2R::GNA14
140,R-HSA-913709,0.0217,0.9902,15,62,0.3672,O-linked glycosylation of mucins,CHST4::B3GNT3::ST6GALNAC2::GALNT5::MUCL1::ST6GALNAC3::ST6GALNAC4::MUC19::GALNTL6::A4GNT::MUC13::MUC5B::B3GNT5::B3GNT7::MUC16
141,R-HSA-1251985,0.0222,0.9925,9,32,0.3721,Nuclear signaling by ERBB4,NRG3::HBEGF::ESR1::NRG1::APOE::PGR::CXCL12::SPARC::SRC
142,R-HSA-983695,0.023,0.9922,9,31,0.3811,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,PIK3AP1::FYN::BLNK::SH3KBP1::LYN::PIK3CD::TRPC1::VAV1::CD22
143,R-HSA-1630316,0.0232,0.987,26,124,0.3811,Glycosaminoglycan metabolism,B3GNT3::HPSE::KERA::VCAN::CSPG4::DCN::CHST13::SLC26A2::EXT1::HS6ST3::DSE::HAS2::HSPG2::CHSY3::PRELP::CHST7::CEMIP::BGN::SDC4::CHST1::DSEL::B3GNT7::CHST3::CD44::HS3ST3B1::HS3ST1
144,R-HSA-8875513,0.0233,0.9981,3,5,0.3811,MET interacts with TNS proteins,ITGB1::MET::TNS3
145,R-HSA-373752,0.0234,0.9902,13,50,0.3811,Netrin-1 signaling,DCC::DSCAM::FYN::MYO10::PRKCQ::NTN4::SRC::TRPC1::TRPC3::TRPC4::ABLIM2::UNC5A::SLIT2
146,R-HSA-211897,0.0237,0.9892,15,64,0.3832,Cytochrome P450 - arranged by substrate type,CYP4F8::CYP2U1::CYP4F22::CYP1A2::CYP2A6::CYP2A7::CYP2E1::CYP4B1::CYP11A1::CYP24A1::CYP26A1::CYP27A1::CYP51A1::CYP2S1::PTGIS
147,R-HSA-8866376,0.0242,0.9981,3,5,0.3893,Reelin signalling pathway,FYN::SH3KBP1::RELN
148,R-HSA-1482925,0.0245,0.994,6,18,0.3912,Acyl chain remodelling of PG,PLA2R1::PLA2G4F::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5
149,R-HSA-3560782,0.0251,0.9902,11,41,0.3988,Diseases associated with glycosaminoglycan metabolism,KERA::VCAN::CSPG4::DCN::SLC26A2::EXT1::HSPG2::PRELP::BGN::SDC4::CHST3
150,R-HSA-420029,0.0254,0.9919,8,28,0.4,Tight junction interactions,CLDN16::CLDN3::CLDN11::CLDN18::CLDN10::CLDN8::CLDN6::CLDN1
151,R-HSA-428930,0.0262,0.9924,7,24,0.4098,Thromboxane signalling through TP receptor,GNA15::GNG10::GNG11::GNGT2::GNG2::TBXA2R::GNA14
152,R-HSA-9009391,0.0264,0.9871,17,77,0.4112,Extra-nuclear estrogen signaling,AKT3::HBEGF::EGFR::ESR1::GNG10::GNG11::GNGT2::HSPB1::MMP2::MMP9::GNG2::BCL2::SRC::TGFA::PIK3R3::CAV1::CAV2
153,R-HSA-71240,0.0267,0.9944,5,14,0.413,Tryptophan catabolism,ACMSD::IDO1::AADAT::KMO::KYNU
154,R-HSA-190241,0.0283,0.9926,6,20,0.4352,FGFR2 ligand binding and activation,FGF1::FGF2::FGF5::FGFR2::FGF20::FGFBP1
155,R-HSA-190377,0.0286,0.9953,4,10,0.4364,FGFR2b ligand binding and activation,FGF1::FGF2::FGFR2::FGFBP1
156,R-HSA-3000480,0.0291,0.9924,6,19,0.4414,Scavenging by Class A Receptors,COL1A2::COL3A1::COL4A1::COL4A2::APOA1::APOE
157,R-HSA-1660661,0.0294,0.9882,11,43,0.4424,Sphingolipid de novo biosynthesis,DEGS2::ACER1::PPM1L::SPTSSB::ALDH3B1::PRKD3::ACER2::SPTLC3::PRKD1::FA2H::SGPP1
158,R-HSA-112314,0.0308,0.9802,38,202,0.4605,Neurotransmitter receptors and postsynaptic signal transmission,TUBB3::TUBB4A::ADCY1::ADCY2::ADCY5::ADCY7::GABBR1::GABRA1::GABRA3::GABRG2::CACNG4::RPS6KA6::GNG10::GNG11::GNGT2::GRIK3::GRIK4::GRIN1::NRG1::TUBB2B::KCNJ2::KCNJ3::KCNJ4::KCNJ15::KCNJ16::MAPT::GNG2::PRKCA::KIF17::SRC::TUBA4A::TUBAL3::GLRA3::CAMK4::CAMK2A::NCALD::TUBB6::LIN7A
159,R-HSA-8964046,0.031,0.9968,3,6,0.4605,VLDL clearance,APOC1::APOC4::APOBR
160,R-HSA-977606,0.0315,0.9871,11,46,0.4655,Regulation of Complement cascade,CFHR3::CR2::C5AR2::CFH::PROS1::SERPING1::C1R::C3::C4BPB::C6::VTN
161,R-HSA-75892,0.0321,0.9929,5,14,0.4669,Platelet Adhesion to exposed collagen,COL1A2::FYN::ITGA1::ITGB1::LYN
162,R-HSA-201451,0.0321,0.9894,8,27,0.4669,Signaling by BMP,FSTL1::BMP10::SMAD9::SMURF2::BMP2::CHRDL1::NOG::ACVRL1
163,R-HSA-205025,0.0322,0.9966,3,6,0.4669,NADE modulates death signalling,BEX3::NGF::NGFR
164,R-HSA-1483166,0.0357,0.9859,10,39,0.515,Synthesis of PA,PLA2R1::GPD1L::ALPI::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5::PLD1::AGPAT4::GPAT3
165,R-HSA-418990,0.0359,0.9867,9,33,0.515,Adherens junctions interactions,CDH2::CDH3::CDH6::CDH7::CDH11::CDH13::NECTIN3::PVR::NECTIN4
166,R-HSA-9609736,0.0376,0.985,10,39,0.5357,Assembly and cell surface presentation of NMDA receptors,TUBB3::TUBB4A::GRIN1::TUBB2B::KIF17::TUBA4A::TUBAL3::CAMK2A::TUBB6::LIN7A
167,R-HSA-5668914,0.0378,0.9745,44,243,0.5358,Diseases of metabolism,KERA::ADAMTS8::ADAMTS7::ADAMTS6::CYP2U1::MUCL1::CYP4F22::ADAMTS14::CSF2RA::VCAN::CSPG4::CYP11A1::CYP24A1::CYP27A1::DCN::ADAMTS16::ADAMTS18::ADAMTS19::SLC26A2::EXT1::THSD7A::GGT1::MUC19::GYS2::HSPG2::ADAMTSL4::PRELP::MUC13::ADAMTS9::BGN::SDC4::THBS1::MUC5B::ADAMTS20::CUBN::AMN::ADAMTS12::ADAMTS10::LARGE1::ADAMTSL1::MUC16::CHST3::ADAMTS3::ADAMTSL2
168,R-HSA-198933,0.0382,0.9781,23,124,0.5363,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,COL1A2::COL3A1::COL17A1::RAET1E::HLA-A::HLA-B::ICAM1::ICAM2::ITGA4::ITGB1::ITGB2::CD200::CRTAM::SLAMF7::PVR::ICAM5::C3::ULBP3::TREML2::CD8A::CD8B::CD22::CD40
169,R-HSA-445717,0.0384,0.983,12,52,0.5363,Aquaporin-mediated transport,ADCY1::ADCY2::ADCY5::ADCY7::GNG10::GNG11::GNGT2::AQP1::AQP5::AQP9::GNG2::AVPR2
170,R-HSA-433692,0.0392,0.9955,3,6,0.5363,Proton-coupled monocarboxylate transport,SLC16A1::SLC16A3::SLC16A7
171,R-HSA-399955,0.0393,0.9908,5,14,0.5363,SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,SEMA3A::FYN::RND1::NRP1::PLXNA4
172,R-HSA-6783589,0.0395,0.9874,7,24,0.5363,Interleukin-6 family signaling,CNTFR::IL31RA::CTF1::CLCF1::IL6::LIF::OSMR
173,R-HSA-888590,0.0398,0.9888,6,19,0.5363,"GABA synthesis, release, reuptake and degradation",CPLX1::ABAT::RIMS1::GAD1::RAB3A::SLC6A11
174,R-HSA-8857538,0.0404,0.9953,3,6,0.5363,PTK6 promotes HIF1A stabilization,LRRK2::HBEGF::EGFR
175,R-HSA-8939256,0.0407,0.9953,3,6,0.5363,RUNX1 regulates transcription of genes involved in WNT signaling,ESR1::FOXP3::RSPO3
176,R-HSA-8949275,0.0408,0.9952,3,6,0.5363,RUNX3 Regulates Immune Response and Cell Migration,ITGA4::RORC::SPP1
177,R-HSA-8963691,0.0412,0.9921,4,11,0.5363,Phenylalanine and tyrosine metabolism,IL4I1::HGD::TAT::ASRGL1
178,R-HSA-3928665,0.0415,0.9814,12,51,0.5363,EPH-ephrin mediated repulsion of cells,VAV3::EFNA3::EFNB3::EPHA2::EPHA3::EPHA5::EPHB2::FYN::LYN::MMP2::MMP9::SRC
179,R-HSA-418038,0.0423,0.9897,5,15,0.5363,Nucleotide-like (purinergic) receptors,ADORA2B::P2RY10::GPR17::P2RY1::P2RY2
180,R-HSA-389977,0.0424,0.9876,6,21,0.5363,Post-chaperonin tubulin folding pathway,TUBB3::TUBB4A::TUBB2B::TUBA4A::TUBAL3::TUBB6
181,R-HSA-193681,0.0424,0.9981,2,3,0.5363,Ceramide signalling,NGF::NGFR
182,R-HSA-8981607,0.0424,0.9981,2,3,0.5363,Intracellular oxygen transport,CYGB::MB
183,R-HSA-5654219,0.0425,0.9895,5,16,0.5363,Phospholipase C-mediated cascade- FGFR1,FGF1::FGF2::FGF5::FGF20::KL
184,R-HSA-391903,0.0425,0.9896,5,15,0.5363,Eicosanoid ligand-binding receptors,CYSLTR1::GPR17::PTGER3::PTGFR::TBXA2R
185,R-HSA-190242,0.0427,0.9894,5,16,0.5363,FGFR1 ligand binding and activation,FGF1::FGF2::FGF5::FGF20::KL
186,R-HSA-211999,0.043,0.9917,4,11,0.5363,CYP2E1 reactions,CYP2A6::CYP2A7::CYP2E1::CYP2S1
187,R-HSA-9619665,0.0432,0.9847,8,28,0.5363,EGR2 and SOX10-mediated initiation of Schwann cell myelination,CYP51A1::LAMA2::LAMB1::LAMC1::MBP::TEAD1::UTRN::SCD5
188,R-HSA-1839122,0.0434,0.9916,4,11,0.5363,Signaling by activated point mutants of FGFR1,FGF1::FGF2::FGF5::FGF20
189,R-HSA-3359462,0.0439,0.998,2,3,0.5363,Defective AMN causes hereditary megaloblastic anemia 1,CUBN::AMN
190,R-HSA-3359463,0.0439,0.998,2,3,0.5363,Defective CUBN causes hereditary megaloblastic anemia 1,CUBN::AMN
191,R-HSA-3772470,0.0441,0.9891,5,15,0.5363,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,WIF1::DKK1::SOST::WNT4::SFRP1
192,R-HSA-1793185,0.0444,0.98,12,50,0.5363,Chondroitin sulfate dermatan sulfate metabolism,VCAN::CSPG4::DCN::CHST13::DSE::HSPG2::CHSY3::CHST7::BGN::SDC4::DSEL::CHST3
193,R-HSA-975634,0.0445,0.9815,10,43,0.5363,Retinoid metabolism and transport,PLB1::LRP12::HSPG2::APOA1::APOE::LRP1::LRP2::RBP1::RBP4::SDC4
194,R-HSA-190704,0.0446,0.9979,2,3,0.5363,Oligomerization of connexins into connexons,GJA1::GJB2
195,R-HSA-190827,0.0446,0.9979,2,3,0.5363,Transport of connexins along the secretory pathway,GJA1::GJB2
196,R-HSA-3928663,0.0446,0.9839,8,30,0.5363,EPHA-mediated growth cone collapse,MYL9::EFNA3::EPHA2::EPHA3::EPHA5::FYN::LYN::SRC
197,R-HSA-111996,0.0447,0.9817,10,39,0.5363,Ca-dependent events,ADCY1::ADCY2::ADCY5::ADCY7::PDE1A::PDE1C::PLA2G4A::PRKCA::CAMK4::CAMK2A
198,R-HSA-9657689,0.0472,0.9977,2,3,0.5641,Defective SERPING1 causes hereditary angioedema,KLKB1::SERPING1
199,R-HSA-372708,0.0477,0.988,5,15,0.5652,p130Cas linkage to MAPK signaling for integrins,FGG::FN1::ITGB3::APBB1IP::SRC
200,R-HSA-428542,0.0478,0.9907,4,10,0.5652,Regulation of commissural axon pathfinding by SLIT and ROBO,DCC::ROBO3::SRC::SLIT2
201,R-HSA-2033519,0.0482,0.9875,5,17,0.5668,Activated point mutants of FGFR2,FGF1::FGF2::FGF5::FGFR2::FGF20
202,R-HSA-418890,0.0485,0.9905,4,10,0.568,Role of second messengers in netrin-1 signaling,DCC::TRPC1::TRPC3::TRPC4
203,R-HSA-354194,0.0492,0.9875,5,15,0.5736,GRB2-SOS provides linkage to MAPK signaling for Integrins ,FGG::FN1::ITGB3::APBB1IP::SRC
204,R-HSA-9658195,0.0497,0.966,42,248,0.5759,Leishmania infection,CALCRL::RAMP2::RAMP1::RAMP3::VAV3::ADCY1::ADCY2::CYSLTR1::CGA::NOXA1::ADCY5::GPR176::ADCY7::ADCYAP1::ADM::ADORA2B::ADRB2::DRD1::FYN::GGT1::GNG10::GNG11::GNGT2::GPR15::GPR20::HTR4::IL1A::IL6::IL18::LYN::MC4R::MYO10::NT5E::GNG2::AVPR2::PTH1R::SRC::C3::VAV1::VIPR1::FZD7::GLP2R
205,R-HSA-170660,0.05,0.9901,4,10,0.5768,Adenylate cyclase activating pathway,ADCY1::ADCY2::ADCY5::ADCY7
206,R-HSA-3296197,0.0506,0.9975,2,3,0.5813,Hydroxycarboxylic acid-binding receptors,HCAR2::HCAR3
207,R-HSA-196807,0.0523,0.9804,8,31,0.5975,Nicotinate metabolism,PARP4::SLC5A8::NMNAT2::QPRT::NNMT::NT5E::PTGIS::PTGS2
208,R-HSA-5676594,0.0531,0.9858,5,17,0.6031,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,BIRC3::LTB::TNFSF14::TNFSF12::CD40
209,R-HSA-140875,0.0533,0.9834,6,22,0.6031,Common Pathway of Fibrin Clot Formation,PROCR::F2R::FGG::SERPINE2::PROS1::CD177
210,R-HSA-5635851,0.0538,0.9972,2,3,0.6055,GLI proteins bind promoters of Hh responsive genes to promote transcription,GLI2::GLI3
211,R-HSA-3560801,0.0545,0.9832,6,20,0.6089,Defective B3GAT3 causes JDSSDHD,VCAN::CSPG4::DCN::HSPG2::BGN::SDC4
212,R-HSA-9014843,0.0546,0.9972,2,3,0.6089,Interleukin-33 signaling,IL1RAP::IL33
213,R-HSA-191650,0.0548,0.9971,2,3,0.6089,Regulation of gap junction activity,GJA1::SRC
214,R-HSA-3560783,0.0551,0.983,6,20,0.6091,"Defective B4GALT7 causes EDS, progeroid type",VCAN::CSPG4::DCN::HSPG2::BGN::SDC4
215,R-HSA-432040,0.056,0.9758,10,43,0.6123,Vasopressin regulates renal water homeostasis via Aquaporins,ADCY1::ADCY2::ADCY5::ADCY7::GNG10::GNG11::GNGT2::AQP1::GNG2::AVPR2
216,R-HSA-983189,0.0561,0.9727,13,58,0.6123,Kinesins,TUBB3::TUBB4A::KLC3::KIF26A::TUBB2B::KIF3C::KIF5A::KIF1A::KIF26B::TUBA4A::TUBAL3::TUBB6::KIFC2
217,R-HSA-4420332,0.0562,0.9826,6,20,0.6123,Defective B3GALT6 causes EDSP2 and SEMDJL1,VCAN::CSPG4::DCN::HSPG2::BGN::SDC4
218,R-HSA-2142688,0.0568,0.9912,3,8,0.6164,Synthesis of 5-eicosatetraenoic acids,GPX1::GPX2::PON3
219,R-HSA-1839130,0.0576,0.9873,4,12,0.6184,Signaling by activated point mutants of FGFR3,FGF1::FGF2::FGF5::FGF20
220,R-HSA-2033514,0.0576,0.9873,4,12,0.6184,FGFR3 mutant receptor activation,FGF1::FGF2::FGF5::FGF20
221,R-HSA-1482788,0.0578,0.9795,7,27,0.6184,Acyl chain remodelling of PC,PLB1::PLA2R1::PLA2G4F::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5
222,R-HSA-3642278,0.0588,0.9968,2,3,0.6231,Loss of Function of TGFBR2 in Cancer,TGFB1::TGFBR2
223,R-HSA-3645790,0.0588,0.9968,2,3,0.6231,TGFBR2 Kinase Domain Mutants in Cancer,TGFB1::TGFBR2
224,R-HSA-844455,0.0594,0.9967,2,3,0.6276,The NLRP1 inflammasome,NLRP1::BCL2
225,R-HSA-420597,0.0598,0.9911,3,7,0.6282,Nectin Necl  trans heterodimerization,NECTIN3::PVR::NECTIN4
226,R-HSA-445144,0.0603,0.9808,6,21,0.6282,Signal transduction by L1,EGFR::ITGA5::ITGB1::ITGB3::L1CAM::NRP1
227,R-HSA-428359,0.0605,0.9966,2,3,0.6282,Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs IMPs VICKZs) bind RNA,IGF2BP3::IGF2BP2
228,R-HSA-6814848,0.0606,0.9909,3,7,0.6282,Glycerophospholipid catabolism,ENPP6::PNPLA7::GDPD3
229,R-HSA-190373,0.0616,0.9861,4,12,0.6363,FGFR1c ligand binding and activation,FGF1::FGF2::FGF5::FGF20
230,R-HSA-5669034,0.0626,0.9772,7,29,0.6412,TNFs bind their physiological receptors,TNFRSF9::TNFRSF11B::TNFRSF1B::TNFSF14::TNFRSF14::TNFSF18::TNFSF15
231,R-HSA-388844,0.063,0.9798,6,20,0.6412,Receptor-type tyrosine-protein phosphatases,IL1RAPL1::SLITRK4::SLITRK5::IL1RAP::SLITRK6::PPFIBP2
232,R-HSA-5654221,0.0631,0.982,5,18,0.6412,Phospholipase C-mediated cascade; FGFR2,FGF1::FGF2::FGF5::FGFR2::FGF20
233,R-HSA-5621480,0.0632,0.9772,7,27,0.6412,Dectin-2 family,MUCL1::FYN::MUC19::LYN::MUC13::MUC5B::MUC16
234,R-HSA-5576894,0.0636,0.9902,3,7,0.643,Phase 1 - inactivation of fast Na+ channels,KCNIP3::KCNIP1::KCND3
235,R-HSA-8964043,0.0641,0.9747,8,33,0.6448,Plasma lipoprotein clearance,PCSK9::APOA1::APOC1::APOC4::APOE::APOBR::CUBN::AMN
236,R-HSA-8866907,0.067,0.9845,4,12,0.671,Activation of the TFAP2 (AP-2) family of transcription factors,CITED4::CITED1::TFAP2B::TFAP2C
237,R-HSA-417957,0.0675,0.9844,4,12,0.6732,P2Y receptors,P2RY10::GPR17::P2RY1::P2RY2
238,R-HSA-399956,0.0678,0.9807,5,16,0.6738,CRMPs in Sema3A signaling,SEMA3A::DPYSL3::FYN::NRP1::PLXNA4
239,R-HSA-1433559,0.0684,0.9805,5,16,0.6768,Regulation of KIT signaling,FYN::LCK::LYN::PRKCA::SRC
240,R-HSA-211979,0.0705,0.9834,4,12,0.6883,Eicosanoids,CYP4F8::CYP4F22::CYP4B1::PTGIS
241,R-HSA-912631,0.0705,0.9764,6,22,0.6883,Regulation of signaling by CBL,FYN::BLNK::LYN::PIK3CD::VAV1::PIK3R3
242,R-HSA-400042,0.0708,0.9736,7,28,0.6883,"Adrenaline,noradrenaline inhibits insulin secretion",ADCY5::ADRA2C::GNG10::GNG11::GNGT2::GNG2::CACNA1D
243,R-HSA-1482839,0.0708,0.9734,7,29,0.6883,Acyl chain remodelling of PE,PLA2R1::PLA2G4F::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5::PLAAT2
244,R-HSA-9032500,0.0711,0.9885,3,7,0.6883,Activated NTRK2 signals through FYN,FYN::BDNF::SRC
245,R-HSA-211958,0.0713,0.9831,4,12,0.6883,Miscellaneous substrates,CYP2U1::CYP4F22::CYP4B1::CYP2S1
246,R-HSA-9619483,0.0717,0.9731,7,28,0.6895,Activation of AMPK downstream of NMDARs,TUBB3::TUBB4A::TUBB2B::MAPT::TUBA4A::TUBAL3::TUBB6
247,R-HSA-6806667,0.0728,0.9667,10,47,0.6967,Metabolism of fat-soluble vitamins,PLB1::LRP12::HSPG2::APOA1::APOE::LRP1::LRP2::RBP1::RBP4::SDC4
248,R-HSA-879518,0.0738,0.9823,4,12,0.7026,Transport of organic anions,SLCO1B1::SLCO1B3::SLCO2A1::SLCO1A2
249,R-HSA-194840,0.0742,0.9528,26,135,0.7026,Rho GTPase cycle,DLC1::VAV3::ARHGAP42::ARHGAP36::RHOV::TIAM2::RHOH::MCF2::ARHGEF35::ARHGEF4::ARHGEF38::RHOJ::ARHGAP31::PREX1::RHOU::ARHGAP22::RAC2::ARAP3::PLEKHG2::VAV1::SYDE1::KALRN::DEPDC7::ARHGAP18::ARHGAP29::STARD8
250,R-HSA-111933,0.0755,0.9673,9,37,0.7026,Calmodulin induced events,ADCY1::ADCY2::ADCY5::ADCY7::PDE1A::PDE1C::PRKCA::CAMK4::CAMK2A
251,R-HSA-111997,0.0755,0.9673,9,37,0.7026,CaM pathway,ADCY1::ADCY2::ADCY5::ADCY7::PDE1A::PDE1C::PRKCA::CAMK4::CAMK2A
252,R-HSA-190239,0.0756,0.9814,4,13,0.7026,FGFR3 ligand binding and activation,FGF1::FGF2::FGF5::FGF20
253,R-HSA-190372,0.0756,0.9814,4,13,0.7026,FGFR3c ligand binding and activation,FGF1::FGF2::FGF5::FGF20
254,R-HSA-5638302,0.0758,0.9867,3,8,0.7026,Signaling by Overexpressed Wild-Type EGFR in Cancer,HBEGF::EGFR::TGFA
255,R-HSA-5638303,0.0758,0.9867,3,8,0.7026,Inhibition of Signaling by Overexpressed EGFR,HBEGF::EGFR::TGFA
256,R-HSA-5083625,0.0773,0.9769,5,17,0.7139,Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),MUCL1::MUC19::MUC13::MUC5B::MUC16
257,R-HSA-9007892,0.0779,0.9931,2,4,0.714,Interleukin-38 signaling,IL1RAPL1::IL1RL2
258,R-HSA-5083636,0.0782,0.9765,5,17,0.714,Defective GALNT12 causes colorectal cancer 1 (CRCS1),MUCL1::MUC19::MUC13::MUC5B::MUC16
259,R-HSA-5654227,0.0782,0.9805,4,13,0.714,Phospholipase C-mediated cascade; FGFR3,FGF1::FGF2::FGF5::FGF20
260,R-HSA-3299685,0.0789,0.967,8,37,0.7169,Detoxification of Reactive Oxygen Species,GPX1::GPX2::GPX3::GPX7::GSTP1::NCF2::GPX8::SOD3
261,R-HSA-390522,0.0791,0.967,8,36,0.7169,Striated Muscle Contraction,TMOD2::MYL2::MYL3::MYL4::TNNC1::TNNT1::TPM2::VIM
262,R-HSA-1663150,0.0811,0.9795,4,13,0.7322,The activation of arylsulfatases,ARSI::ARSH::STS::ARSL
263,R-HSA-9646399,0.082,0.9634,9,41,0.7331,Aggrephagy,TUBB3::TUBB4A::CFTR::DYNC1I1::TUBB2B::TUBA4A::VIM::TUBAL3::TUBB6
264,R-HSA-209563,0.0821,0.9925,2,4,0.7331,Axonal growth stimulation,NGF::NGFR
265,R-HSA-112308,0.0823,0.9795,4,12,0.7331,Presynaptic depolarization and calcium channel opening,CACNG4::CACNA2D1::CACNB1::CACNB4
266,R-HSA-375280,0.0825,0.9632,9,41,0.7331,Amine ligand-binding receptors,HRH3::ADRA1B::ADRA2C::ADRB2::DRD1::HRH1::HTR1D::HTR2C::HTR4
267,R-HSA-392451,0.0831,0.9706,6,24,0.7357,G beta-gamma signalling through PI3Kgamma,AKT3::PIK3R5::GNG10::GNG11::GNGT2::GNG2
268,R-HSA-1236394,0.0839,0.9574,12,57,0.7404,Signaling by ERBB4,NRG3::HBEGF::EGFR::ESR1::GABRA1::GABRG2::NRG1::APOE::PGR::CXCL12::SPARC::SRC
269,R-HSA-390696,0.0853,0.9842,3,8,0.7499,Adrenoceptors,ADRA1B::ADRA2C::ADRB2
270,R-HSA-6805567,0.0858,0.9418,31,212,0.7514,Keratinization,KLK8::KRT80::DSG4::DSG1::DSG3::FLG::CASP14::KLK5::KLK13::KRT79::LIPM::KRT2::KRT4::KRT14::KRT17::KRT32::KRT33B::KRT34::KRT81::KRT83::KRT85::SPINK6::KLK14::PKP2::SPRR2D::KRTAP4-8::KRTAP2-3::KRTAP1-5::KRTAP3-1::KRTAP4-1::KRTAP2-4
271,R-HSA-909733,0.0866,0.9541,13,70,0.756,Interferon alpha beta signaling,IFITM2::IFIT5::HLA-A::HLA-B::IFIT2::IFIT1::IFIT3::IFNA1::IRF7::MX2::PSMB8::RNASEL::BST2
272,R-HSA-437239,0.0892,0.9576,10,46,0.7755,Recycling pathway of L1,TUBB3::TUBB4A::RPS6KA6::TUBB2B::L1CAM::MSN::SRC::TUBA4A::TUBAL3::TUBB6
273,R-HSA-77108,0.0921,0.9909,2,4,0.7967,Utilization of Ketone Bodies,BDH1::OXCT2
274,R-HSA-5083632,0.0923,0.9705,5,18,0.7967,Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),MUCL1::MUC19::MUC13::MUC5B::MUC16
275,R-HSA-5620924,0.0927,0.9536,11,54,0.7973,Intraflagellar transport,TUBB3::TUBB4A::TUBB2B::KIF3C::IFT57::KIF17::TUBA4A::DYNC2H1::IFT74::DYNLRB2::TUBB6
276,R-HSA-8847993,0.0933,0.9752,4,13,0.7996,ERBB2 Activates PTK6 Signaling,NRG3::HBEGF::EGFR::NRG1
277,R-HSA-416482,0.0943,0.946,16,80,0.802,G alpha (12 13) signalling events,VAV3::ADRA1B::TIAM2::GNG10::GNG11::GNGT2::MCF2::ARHGEF35::ARHGEF4::GNG2::ARHGEF38::PREX1::PLEKHG2::TBXA2R::VAV1::KALRN
278,R-HSA-3656535,0.0943,0.9906,2,4,0.802,TGFBR1 LBD Mutants in Cancer,TGFB1::TGFBR2
279,R-HSA-112310,0.0963,0.9516,11,51,0.8144,Neurotransmitter release cycle,CPLX1::CHAT::ABAT::RIMS1::GAD1::NAAA::RAB3A::SLC1A1::SLC1A3::SLC6A11::LIN7A
280,R-HSA-8866906,0.0968,0.9902,2,4,0.8144,TFAP2 (AP-2) family regulates transcription of other transcription factors,PITX2::TFAP2C
281,R-HSA-2187338,0.0972,0.9418,18,99,0.8144,Visual phototransduction,SDR9C7::PLB1::AWAT2::LRP12::GUCY2D::HSPG2::APOA1::APOE::LRP1::LRP2::PDE6B::PRKCA::PRKCQ::RBP1::RBP4::SDC4::STRA6::RGS9
282,R-HSA-446353,0.0974,0.9684,5,18,0.8144,Cell-extracellular matrix interactions,FLNA::FLNC::ITGB1::FBLIM1::LIMS2
283,R-HSA-9026527,0.0977,0.99,2,4,0.8144,Activated NTRK2 signals through PLCG1,NTF4::BDNF
284,R-HSA-163841,0.098,0.9545,9,42,0.8144,"Gamma carboxylation, hypusine formation and arylsulfatase activation",F7::GAS6::ARSI::ARSH::STS::ARSL::PROS1::EIF5A2::TPST1
285,R-HSA-390650,0.0983,0.9899,2,4,0.8144,Histamine receptors,HRH3::HRH1
286,R-HSA-389960,0.0985,0.9632,6,25,0.8144,Formation of tubulin folding intermediates by CCT TriC,TUBB3::TUBB4A::TUBB2B::TUBA4A::TUBAL3::TUBB6
287,R-HSA-156580,0.1003,0.9396,18,102,0.8246,Phase II - Conjugation of compounds,GLYAT::ACSM1::GGT6::CYP1A2::SLC26A2::ESD::SULT4A1::GGT1::GSTA3::GSTM3::GSTM5::GSTP1::NNMT::SULT1A1::UGT2B15::UGT2B17::TPST1::NAT1
288,R-HSA-418886,0.1005,0.98,3,8,0.8246,Netrin mediated repulsion signals,DCC::SRC::UNC5A
289,R-HSA-189483,0.101,0.972,4,14,0.8246,Heme degradation,SLCO1B1::SLCO1B3::BLVRB::ABCG2
290,R-HSA-159763,0.1011,0.9791,3,9,0.8246,Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,F7::GAS6::PROS1
291,R-HSA-1502540,0.102,0.972,4,13,0.8284,Signaling by Activin,FSTL3::FST::INHBA::INHBB
292,R-HSA-1296025,0.1023,0.9893,2,4,0.8284,ATP sensitive Potassium channels,ABCC9::KCNJ11
293,R-HSA-6809583,0.1035,1,1,1,0.8336,Retinoid metabolism disease events,RBP4
294,R-HSA-1296053,0.1036,0.9891,2,4,0.8336,Classical Kir channels,KCNJ2::KCNJ4
295,R-HSA-420092,0.1058,0.9556,7,33,0.8482,Glucagon-type ligand receptors,ADCYAP1::GNG10::GNG11::GNGT2::GNG2::VIPR1::GLP2R
296,R-HSA-212718,0.1072,0.9772,3,9,0.854,EGFR interacts with phospholipase C-gamma,HBEGF::EGFR::TGFA
297,R-HSA-166658,0.1073,0.9446,11,57,0.854,Complement cascade,CFHR3::CR2::C5AR2::CFH::PROS1::SERPING1::C1R::C3::C4BPB::C6::VTN
298,R-HSA-1300642,0.1091,0.9766,3,9,0.8634,Sperm Motility And Taxes,CATSPER1::KCNU1::CATSPERB
299,R-HSA-194306,0.1092,0.9881,2,4,0.8634,Neurophilin interactions with VEGF and VEGFR,NRP2::NRP1
300,R-HSA-197264,0.1138,0.9609,5,19,0.896,Nicotinamide salvaging,PARP4::SLC5A8::NNMT::PTGIS::PTGS2
301,R-HSA-6802948,0.114,0.9483,8,36,0.896,Signaling by high-kinase activity BRAF mutants,FGG::CNKSR2::FN1::ITGB3::ARRB1::APBB1IP::SRC::KSR1
302,R-HSA-5626467,0.1145,0.9513,7,31,0.897,RHO GTPases activate IQGAPs,TUBB3::TUBB4A::IQGAP2::TUBB2B::TUBA4A::TUBAL3::TUBB6
303,R-HSA-391908,0.1163,0.9744,3,9,0.905,Prostanoid ligand receptors,PTGER3::PTGFR::TBXA2R
304,R-HSA-8955332,0.1163,0.9469,8,37,0.905,Carboxyterminal post-translational modifications of tubulin,TUBB3::TUBB4A::TUBB2B::LRRC49::TUBA4A::TUBAL3::TUBB6::AGBL4
305,R-HSA-8963684,0.1178,0.9846,2,5,0.911,Tyrosine catabolism,HGD::TAT
306,R-HSA-209931,0.118,0.9846,2,5,0.911,Serotonin and melatonin biosynthesis,DDC::ASMT
307,R-HSA-156590,0.1183,0.9487,7,35,0.911,Glutathione conjugation,GGT6::ESD::GGT1::GSTA3::GSTM3::GSTM5::GSTP1
308,R-HSA-399997,0.1195,0.9733,3,9,0.9146,Acetylcholine regulates insulin secretion,GNA15::PRKCA::GNA14
309,R-HSA-2024101,0.1197,0.9647,4,14,0.9146,CS DS degradation,VCAN::CSPG4::DCN::BGN
310,R-HSA-8866423,0.1204,0.984,2,5,0.9146,VLDL assembly,APOC1::APOC4
311,R-HSA-2179392,0.1209,0.9729,3,9,0.9146,EGFR Transactivation by Gastrin,HBEGF::EGFR::PRKCA
312,R-HSA-416700,0.1209,0.9576,5,19,0.9146,Other semaphorin interactions,PLXND1::ITGA1::ITGB1::SEMA7A::PLXNA4
313,R-HSA-556833,0.121,0.8995,110,729,0.9146,Metabolism of lipids,SLCO1B1::STARD10::CGA::SLC27A3::GLIPR1::CHAT::CYP4F8::CYP2U1::OSBPL5::ACOT4::DEGS2::ACER1::CYP4F22::ENPP6::STARD4::PNPLA5::PLB1::PPM1L::CYP1A2::CYP2E1::CYP4B1::CYP11A1::FAAH2::AWAT2::CYP24A1::CYP27A1::CYP51A1::DBI::SPTSSB::FAAH::FABP4::FABP3::FABP5::ACSL4::ALDH3B1::FHL2::PLA2R1::AKR1B1::GPD1L::PIK3R5::PRKD3::ALOX15B::ALPI::PLA2G4F::ACOT11::OSBPL3::TIAM2::GGT1::ANKRD1::INPP5J::TNFRSF21::SLCO1B3::GPX1::GPX2::GRHL1::PLA2G2E::HMGCS2::HSD3B1::APOA1::ARSI::ACER2::ARSH::PNPLA7::AGMO::LRP2::STS::ARSL::NPAS2::G0S2::HSD17B11::PIK3CD::PLA2G2A::PLA2G4A::PLA2G5::PLD1::PON3::ELOVL2::PLAAT2::SPTLC3::MTMR8::PRKD1::AGPAT4::PTGIS::PTGS2::BCHE::PLEKHA2::BDH1::OXCT2::ACOT6::ETNPPL::SLCO1A2::ELOVL4::THRSP::UGT8::FA2H::GDPD3::SCD5::MOGAT2::CUBN::SLC44A4::SGPP1::ACOX2::PIP5K1B::GPAT3::PIK3R3::AGPS::CAV1::HACD1::CPNE6::PCYT1B
314,R-HSA-500657,0.1262,0.9545,5,21,0.9505,Presynaptic function of Kainate receptors,GNG10::GNG11::GNGT2::GRIK3::GNG2
315,R-HSA-5654688,0.1283,0.9535,5,21,0.9635,SHC-mediated cascade-FGFR1,FGF1::FGF2::FGF5::FGF20::KL
316,R-HSA-451326,0.1289,0.9433,7,32,0.9639,Activation of kainate receptors upon glutamate binding,GNG10::GNG11::GNGT2::GRIK3::GRIK4::GNG2::NCALD
317,R-HSA-211935,0.13,0.9599,4,15,0.9639,Fatty acids,CYP4F8::CYP4F22::CYP2A7::CYP4B1
318,R-HSA-5578775,0.1302,0.9304,11,55,0.9639,Ion homeostasis,ABCC9::FKBP1B::KCNJ11::ATP2A3::FXYD1::FXYD3::FXYD7::FXYD6::SLC8A1::TRPC1::CAMK2A
319,R-HSA-5690714,0.1302,0.9819,2,5,0.9639,CD22 mediated BCR regulation,LYN::CD22
320,R-HSA-5602498,0.1304,0.9689,3,10,0.9639,MyD88 deficiency (TLR2 4),TLR6::TLR1::TLR2
321,R-HSA-193648,0.1314,0.9276,12,58,0.9676,NRAGE signals death through JNK,VAV3::TIAM2::MCF2::ARHGEF35::NGF::NGFR::ARHGEF4::ARHGEF38::PREX1::PLEKHG2::VAV1::KALRN
322,R-HSA-8873719,0.1322,0.9267,12,64,0.9676,RAB geranylgeranylation,RAB32::RAB42::RAB38::RAB26::RAB15::RAB19::RAB9B::RAB25::RAB3A::RAB3B::RAB27B::RAB34
323,R-HSA-5654726,0.1322,0.9413,7,33,0.9676,Negative regulation of FGFR1 signaling,SPRY2::FGF1::FGF2::FGF5::FGF20::SRC::KL
324,R-HSA-418885,0.1335,0.9589,4,14,0.9699,DCC mediated attractive signaling,DCC::FYN::SRC::ABLIM2
325,R-HSA-159740,0.1344,0.9675,3,10,0.9699,Gamma-carboxylation of protein precursors,F7::GAS6::PROS1
326,R-HSA-391906,0.1346,0.9809,2,5,0.9699,Leukotriene receptors,CYSLTR1::GPR17
327,R-HSA-168256,0.1349,0.8799,295,2097,0.9699,Immune System,AKT3::TRIM10::EBI3::CRISP3::SIRPB1::TLR6::TUBB3::TUBB4A::BTN2A2::VAV3::IFITM2::TRIM3::NRG3::CTSC::IQGAP2::HPSE::CFHR3::GLIPR1::RIPK3::IL1RAPL1::IRAK3::TRIM9::PGLYRP2::CGAS::FBXO17::GBP5::CISH::IL22RA2::MUCL1::PIK3AP1::SERPINA3::FBXO27::CNN2::CNTFR::COL1A2::COL3A1::BPIFB6::COL17A1::IL31RA::RAET1E::CR2::BPIFA2::ASB15::CSF1::CSF2::CSF2RA::KLC3::CTF1::CTSE::CTSV::RNF217::ATP6V0E2::IFNLR1::DYNC1I1::DSG1::HBEGF::DUSP4::DUSP9::S1PR1::EGFR::UNC13D::FABP5::ALDH3B1::RNF182::FBXL13::FGF1::FGF2::FGF5::FGFR2::FGG::MRAS::NLRP1::CNKSR2::SARM1::NFASC::FLNA::FBXL7::FN1::COTL1::CLCF1::FPR1::TRIM29::IFIT5::ATP6V0D2::IL27::FYN::RASGRP3::QPCT::METTL7A::KIF26A::FBXO2::GATA3::FGF20::GBP1::GDNF::GFRA1::GHR::C5AR2::MUC19::FBXL22::ANGPT1::GRIN1::CD274::CXCL1::CXCL2::GSTP1::BLNK::SH3KBP1::ANXA1::ANXA2::CFH::NRG1::HLA-A::HLA-B::HLA-DMB::HLA-DOB::HLA-DQA1::BIRC3::ICAM1::S100A7A::ICAM2::STING1::IFIT2::IFIT1::IFIT3::IFNA1::TUBB2B::IL1A::IL1RAP::IL6::IL7R::CXCL8::IL12B::IL12RB2::TNFRSF9::IL18::IRAK2::IRF7::ITGA4::ITGB1::ITGB2::ITGB3::KIF3C::KIF5A::HRNR::FLG2::LBP::LCK::LIF::LMO7::DEFB132::LTB::LYN::ARRB1::ART1::MET::MID1::MME::MMP2::MMP9::CD200::MSN::MX2::MYO10::CEACAM6::NCF2::NFATC2::OLR1::TNFRSF11B::SERPINB2::IL20::TRAT1::KLHL5::RAB9B::PLAC8::EVL::PDGFRB::ASB2::CALML5::SERPINB10::PIGR::PIK3CD::PLA2G2A::PLAU::PLAUR::PLD1::APBB1IP::ACP3::PRCP::RNF130::PRKCQ::PRKG2::MAPK10::PRL::PRLR::CRTAM::PROS1::PRSS3::MUC13::PSMB8::CD177::PTGS2::SLAMF7::PTPRB::PTPRN2::PTX3::PVR::PYGL::RHOU::RAB3A::RAC2::RAG1::IL22RA1::BCL2::RET::RNASEL::RORC::S100A1::S100A7::S100A8::S100A12::SERPINB3::CCL20::CRLF2::SMURF2::SLC2A3::SLC11A1::FSCN1::SOX2::SRC::BST2::TAP2::ZEB1::BTN1A1::TEK::TGFA::TGFB1::TIMP1::TIMP2::ICAM5::TLR1::TLR2::SERPING1::TNFAIP3::TNFRSF1B::C1R::C3::TRPC1::C4BPB::TUBA4A::MUC5B::C6::VAV1::VIM::VTN::XDH::IL1R2::TRIM48::ULBP3::TUBAL3::TREML2::BPIFB2::PDCD1LG2::ZBP1::CAMK2A::CAMP::CARD11::TUBB6::LNX1::PIK3R3::CTSF::TNFSF14::TNFSF12::TNFRSF14::IL1RL2::KSR1::TNFSF18::IL33::OSMR::IL32::CD8A::CD8B::BPIFB1::CD22::KL::MUC16::AIM2::RASAL2::CD40::CD44::CD74::ADGRE5::CDA::MRC2::TNFSF15
328,R-HSA-5619052,0.1351,1,1,1,0.9699,Defective SLC9A9 causes autism 16 (AUTS16),SLC9A9
329,R-HSA-5578996,0.1357,1,1,1,0.9699,Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),CYP27A1
330,R-HSA-159782,0.1358,0.967,3,10,0.9699,Removal of aminoterminal propeptides from gamma-carboxylated proteins,F7::GAS6::PROS1
331,R-HSA-5654689,0.1359,0.9499,5,21,0.9699,PI-3K cascade-FGFR1,FGF1::FGF2::FGF5::FGF20::KL
332,R-HSA-170670,0.1365,0.9576,4,14,0.9699,Adenylate cyclase inhibitory pathway,ADCY1::ADCY2::ADCY5::ADCY7
333,R-HSA-211859,0.1366,0.9014,34,213,0.9699,Biological oxidations,GLYAT::CYP4F8::CYP2U1::ACSM1::GGT6::CYP4F22::CYP1A2::CYP2A6::CYP2A7::CYP2E1::CYP4B1::CYP11A1::CYP24A1::CYP26A1::CYP27A1::CYP51A1::SLC26A2::ESD::AKR7A3::SULT4A1::GGT1::GSTA3::GSTM3::GSTM5::GSTP1::CYP2S1::NNMT::SMOX::PTGIS::SULT1A1::UGT2B15::UGT2B17::TPST1::NAT1
334,R-HSA-9656223,0.1372,0.9314,9,43,0.9711,Signaling by RAF1 mutants,FGG::CNKSR2::FN1::ITGB3::ARRB1::APBB1IP::SRC::CAMK2A::KSR1
335,R-HSA-5619058,0.1385,1,1,1,0.9751,"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",SLCO1B3
336,R-HSA-5654727,0.1395,0.937,7,34,0.9751,Negative regulation of FGFR2 signaling,SPRY2::FGF1::FGF2::FGF5::FGFR2::FGF20::SRC
337,R-HSA-5579005,0.1396,1,1,1,0.9751,"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",CYP4F22
338,R-HSA-193697,0.1403,0.9653,3,10,0.9751,p75NTR regulates axonogenesis,MCF2::NGF::NGFR
339,R-HSA-6785631,0.1407,0.9553,4,15,0.9751,ERBB2 Regulates Cell Motility,NRG3::HBEGF::EGFR::NRG1
340,R-HSA-447041,0.1409,0.9661,3,9,0.9751,CHL1 interactions,ITGA1::ITGB1::NRP1
341,R-HSA-5223345,0.1414,0.9413,6,26,0.9751,Miscellaneous transport and binding events,ADD2::ADD3::DMTN::NIPAL4::PIP::AZGP1
342,R-HSA-5619110,0.1417,1,1,1,0.9751,"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",SLCO1B1
343,R-HSA-1638091,0.1417,0.9229,11,55,0.9751,Heparan sulfate heparin (HS-GAG) metabolism,HPSE::VCAN::CSPG4::DCN::EXT1::HS6ST3::HSPG2::BGN::SDC4::HS3ST3B1::HS3ST1
344,R-HSA-5619095,0.142,1,1,1,0.9751,"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",SLCO2A1
345,R-HSA-1236977,0.1422,0.9639,3,11,0.9751,Endosomal Vacuolar pathway,CTSV::HLA-A::HLA-B
346,R-HSA-2023837,0.144,1,1,1,0.9816,Signaling by FGFR2 amplification mutants,FGFR2
347,R-HSA-8853333,0.144,1,1,1,0.9816,Signaling by FGFR2 fusions,FGFR2
348,R-HSA-5579010,0.1446,1,1,1,0.9816,"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",CYP24A1
349,R-HSA-211957,0.1451,1,1,1,0.9816,Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2,CYP1A2
350,R-HSA-4086398,0.146,0.9176,12,62,0.9816,Ca2+ pathway,FZD2::GNG10::GNG11::GNGT2::PDE6B::GNG2::PRKCA::PRKG2::TCF7::WNT11::CAMK2A::FZD6
351,R-HSA-8866904,0.1463,0.9632,3,10,0.9816,Negative regulation of activity of TFAP2 (AP-2) family transcription factors,TFAP2B::TFAP2C::KCTD15
352,R-HSA-139853,0.1474,0.9523,4,15,0.9816,Elevation of cytosolic Ca2+ levels,P2RX2::P2RX5::TRPC3::P2RX6
353,R-HSA-74182,0.1477,0.9626,3,10,0.9816,Ketone body metabolism,HMGCS2::BDH1::OXCT2
354,R-HSA-5619104,0.149,1,1,1,0.9816,Defective SLC12A1 causes Bartter syndrome 1 (BS1),SLC12A1
355,R-HSA-5619067,0.1492,1,1,1,0.9816,Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),SLC1A1
356,R-HSA-163359,0.1493,0.9316,7,33,0.9816,Glucagon signaling in metabolic regulation,ADCY1::ADCY2::ADCY5::ADCY7::GNG10::GNG11::GNG2
357,R-HSA-74259,0.1499,0.9502,4,17,0.9816,Purine catabolism,GPX1::NT5E::XDH::GDA
358,R-HSA-5619062,0.1503,1,1,1,0.9816,Defective SLC1A3 causes episodic ataxia 6 (EA6),SLC1A3
359,R-HSA-1250342,0.1504,0.9616,3,10,0.9816,PI3K events in ERBB4 signaling,NRG3::HBEGF::NRG1
360,R-HSA-8941284,0.1506,0.9771,2,5,0.9816,RUNX2 regulates chondrocyte maturation,GLI2::RUNX2
361,R-HSA-5619068,0.1508,1,1,1,0.9816,Defective SLC2A10 causes arterial tortuosity syndrome (ATS),SLC2A10
362,R-HSA-5619092,0.1516,1,1,1,0.9816,"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",SLC9A6
363,R-HSA-5579011,0.152,1,1,1,0.9816,"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",CYP2U1
364,R-HSA-428157,0.1521,0.9056,16,89,0.9816,Sphingolipid metabolism,DEGS2::ACER1::PPM1L::SPTSSB::ALDH3B1::PRKD3::ARSI::ACER2::ARSH::STS::ARSL::SPTLC3::PRKD1::UGT8::FA2H::SGPP1
365,R-HSA-975574,0.1522,1,1,1,0.9816,Reactions specific to the hybrid N-glycan synthesis pathway,MGAT3
366,R-HSA-1483206,0.1525,0.8977,22,128,0.9816,Glycerophospholipid biosynthesis,STARD10::CHAT::OSBPL5::PLB1::AWAT2::PLA2R1::GPD1L::ALPI::PLA2G4F::PLA2G2E::PLA2G2A::PLA2G4A::PLA2G5::PLD1::PLAAT2::AGPAT4::BCHE::ETNPPL::SLC44A4::GPAT3::CPNE6::PCYT1B
367,R-HSA-2142850,0.1547,0.976,2,5,0.9816,Hyaluronan biosynthesis and export,HAS2::CEMIP
368,R-HSA-193993,0.1551,0.9741,2,6,0.9816,Mineralocorticoid biosynthesis,CGA::HSD3B1
369,R-HSA-418889,0.1553,0.9598,3,10,0.9816,Caspase activation via Dependence Receptors in the absence of ligand,DAPK1::DCC::UNC5A
370,R-HSA-140837,0.1554,0.9397,5,22,0.9816,Intrinsic Pathway of Fibrin Clot Formation,KLKB1::SERPINE2::PRCP::PROS1::SERPING1
371,R-HSA-1971475,0.1556,0.9336,6,26,0.9816,A tetrasaccharide linker sequence is required for GAG synthesis,VCAN::CSPG4::DCN::HSPG2::BGN::SDC4
372,R-HSA-5619054,0.1556,1,1,1,0.9816,"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",SLC4A4
373,R-HSA-389513,0.156,0.9397,5,21,0.9816,CTLA4 inhibitory signaling,AKT3::FYN::LCK::LYN::SRC
374,R-HSA-3560792,0.1561,1,1,1,0.9816,Defective SLC26A2 causes chondrodysplasias,SLC26A2
375,R-HSA-9669938,0.1569,0.9397,5,20,0.9816,Signaling by KIT in disease,FYN::LCK::LYN::SRC::PIK3R3
376,R-HSA-9670439,0.1569,0.9397,5,20,0.9816,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",FYN::LCK::LYN::SRC::PIK3R3
377,R-HSA-5682294,0.1571,1,1,1,0.9816,Defective ABCA12 causes ARCI4B,ABCA12
378,R-HSA-73614,0.1573,0.9582,3,11,0.9816,Pyrimidine salvage,UPP1::PUDP::CDA
379,R-HSA-195721,0.1573,0.8793,46,298,0.9816,Signaling by WNT,FRAT1::WIF1::PRICKLE1::DKK1::HECW1::FZD2::PYGO1::GNG10::GNG11::GNGT2::ROR1::ROR2::SOST::DACT1::WNT16::PDE6B::GNG2::WNT4::H2AJ::PRKCA::PRKG2::PSMB8::VANGL2::RAC2::SFRP1::SMURF2::SOX2::SOX3::TCF7::TLE4::WNT3::WNT6::WNT7A::WNT11::WLS::WNT10A::WNT5B::CAMK2A::AXIN2::FZD6::FZD7::SOX7::PIP5K1B::RSPO3::LGR5::CAV1
380,R-HSA-9032759,0.1579,0.9752,2,5,0.9825,NTRK2 activates RAC1,FYN::BDNF
381,R-HSA-1489509,0.1594,0.9176,9,43,0.9868,DAG and IP3 signaling,ADCY1::ADCY2::ADCY5::ADCY7::PDE1A::PDE1C::PRKCA::CAMK4::CAMK2A
382,R-HSA-936837,0.1594,0.911,11,57,0.9868,Ion transport by P-type ATPases,ATP8B3::ATP13A5::ATP2A3::FXYD1::FXYD3::FXYD7::FXYD6::ATP10D::CAMK2A::ATP13A4::ATP2C2
383,R-HSA-388479,0.1607,0.9725,2,6,0.9925,Vasopressin-like receptors,AVPR1A::AVPR2
